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EDITORIAL 
The wonders of the gastrointestinal tract 
Melissa J. MacPherson, PhD (Meds 2014) 
The human gastrointestinal (G I) tract is an impress ive 9 m long, 1 extending from gums to bum. Its surface area is an astounding 4500 m2 all packed neatl y into the thorac ic and abdominal cav i-
ti es of the human body! 1 It compri ses an incredibly complex set of or-
gans including the esophagus, tomach, li ver, gall bladder, pancreas, in-
testines, and colon. It is the site of digestion, nutrient absorption, waste 
excretion and the primary site of metaboli sm. Without the G I tract, our 
bodies couldn 't function. It 's no wonder that the fi eld of gastroenterol-
ogy is enormous. Unfo rtunately. our current UWOMJ issue prov ide 
only a small snapshot of its breadth. One of its recurring themes is the 
use of technology in the treatment and diagnosis of di sease, which sever-
al of our department have chosen to highlight. A you read these pages, 
you will learn about radiofrequency ablation in the treatment of li ver 
tumours and colonoscopy in the screening and diagnos is of colorectal 
cancers. 
Other authors have chosen to highlight spec ifi c di seases and their 
management. You will read about a curiou pre entation of adult intu -
susception and the use of acupuncture in the management of irritable 
bowel syndrome. Michae l Verbora di scusses the progression of a rare 
case of gastri c heterotopia in the rectum. Arthur Ling has written an 
interesting arti cle outlining the use of fecal microbiota transplantation 
and metagenomics in gastroenterology. 
A number of other arti cles are also not to be missed. Niran Argintaru 
and Jonathan Fairbairn from our department of ethics and law have writ-
ten a thought provoking piece regarding the ethical and legal complex i-
ties of li ver organ donation. The department of hea lth promotion di -
cusses the importance of nutriti onal knowledge and counseling among 
medical profess ionals. The hi story of medicine department has written 
an intringuing article on the di scovery of the causati ve agent of duode-
nal ulcers and the reluctance of the medical profession to embrace the 
hypothes is of an infectious cause. 
In every issue of the UWOMJ we interview a local phys ician or sc i-
enti st. In thi s edition we had the pri vilege of interviewing Dr. John 
Howard, a pediatri c gastroenterologist who also teaches us during our G I 
curri culum . The profil es arti cle detailing hi s career is not to be missed. 
I hope that you enjoy this issue of the UWOMJ and learn a bit more 
about the G I system as we take an adventure together down the gastro-
intestinal tract! 
REFERENCES 
I. The human digesti ve tract. Encyclopedia Brittanica [internet]. [cited 20 12 Oct 
20) Avai lable from: http://wviw. britanni ca.com/ EBchecked/topi c/ I 08 1754/ 
human-digesti ve-system 
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FEATURE ARTICLE 
Gastric heterotopia in the rectum: progression of 
disease 
Michael Verbora (Meds 2013) 
Faculty Reviewer: Dr. John Howard , MD, FRCP (Department of Medicine and Pediatrics) 
Gastric heterotopia is a condition whereb) ga tric muco a i di -covered outside of its origin. Ga tric heterotopia \\ ithin the rec-tum is rather rare. To date les than 50 ca es have been reported .' 
To our knO\vledge. no case have been reported in which there is are-
view of progression. or elimination. of di ea e over time. We describe a 
case of a patient from age 5 to 24 and report on ymptoms and effective-
ne of everal treatment for heterotopic gastri c mucosa in the rectum . 
A 5 year-old bO) pre en ted to the mergenc) Department \\'ith rec-
tal bleeding. He mentions a three-day histor) of constipation. He \ a 
treated \\'ith a fleet enema and prescribed mineral oi l and told to return 
if further bleedi ng returned . barium enema was negati ve at thi time. 
He eventually is referred to gastroenterology for further investi gati on 
after complai ning of rectal bleeding four year after his initial presenta-
ti on. 
On history. the 9-year-old boy mention con tinued painle . bright 
red bleeding per rectum (BRBPR) several times per month. Despi te the 
bleeding. he is currently plotting along the 60'h percentile for height and 
"eight. Pa t medical hi tOr)' \\aS significant for asthma and family histo-
ry revealed rectal polyps in hi father. A previous trial of metronidazole 
did not improve his ymptom . Both a rev iew of ystems and phy ical 
exam were unremarkable. A fl ex ible igmoido copy was performed in 
clinic that day. A large multi- lobular ses ile po lyp was discovered just 
in ide the rectum and multip le biopsies were taken. Patho logy from the 
recta l le ion showed co lonic muco a w ith pecialized ga tri c type mu-
co a. lands were straight and lined by parietal and chief ce ll (gastri c 
mucosa markers) with no evidence of ero ion or ulceration. 1/elico-
bacter pylori, a bacteria that cau e ~eptic ulcer di ea e. wa not pre ent. 
One month later. the bo) wa scheduled for co lona cop ic fulguration 
of the rectal heterotopia. A n ovo id lesion approximately Scm in length 
and 3cm in w idth wi th gastri c rugae was removed using electocautery. 
Once again. pathology confirmed ga tri c type muco a without H. pylori. 
He was pre cribed 20mg omeprazo le. which rc olvcd bleeding. 
A t age 17. he complains of similar epi odes ofBRBPR . He mentions 
that epi odes of constipati on coi ncide wi th hi ep i odes of rectal bleed-
ing. A econd 3x4cm lesion with gastri c rugae wa removed via argon 
pia rn a coagulation. 
l ie pre ents again at age 24 with everal epi ode of rectal bleed ing. 
He mentions that an over the counter we ight lo s upplement that he 
began taking has improved the bleed ing and increa cd hi bowel move-
ment to 3-4 time per day. On igmoido copy nothing i visualized. lie 
was sched uled for repeat co lona copy. 
DISCUSSION 
In pediatri c tudics, the rati o preva lence of ga tric heterotop ia in the 
rectum is tw ice that for males with a mean age of 5 years old. Hetero-
topic gastric muco a ha been discovered in all area of the ga troin -
testi nal tract. 2 It is most common ly found w ithin the e ophagu . The 
exact mechanism for the development of heterotop ic ga tri c muco a has 
yet to be determined . number of theorie ex ist including. the abnor-
mal regenerative process following de truction of normal mucosa or the 
competing theory that an error of differentiation of pluripotent endo-
denn ce lls during embryonic development leads to heterotopic gastric 
mucosa.3 
Gastric heterotopia l) pica ll) pre ent with painless bleeding: hO\ -
ever. case ha e been reported \\ ith more eriou complication uch 
as major ga trointe tina I bleeding. bowel perforation. megacolon. intus-
susception, peri anal fi stula and rectovesica l fistu la.3 H. pylori has al o 
been di covered a an active in fection in gastric heterotopia in a case of 
a 5 year-old boy. ~ Infection can lead to ulceration and evere bleeding. 
The definitive diagno is occur via analys is of the biop ied tissue. 
Typicall) the patholog) is that of fundic-l)•pe muco a but. case report 
have reported le ion containing ga tric bod). p) loric. antraL chief. sa li-
ary and parietal cell \\ ithin the ti sue ample.5 
Treatment at thi point in time for ga tri c heterotopia lack con i ten-
cy and evidence. orne argue that the gastric mucosa has the potential 
to become malignant. a has been di covered for heterotopic gastric mu-
co a in the esophagus. and thus should be exc i ed.6 To date there are no 
reports of a malignant gastri c heterotopia within the rectum . ucce sful 
treatment to suppre the bleeding include proton pump inhibitor or 
H2 receptor blocker. a-infection\\ ith Helicobacter pylori may warrant 
triple therapy \\ ith anti biotics and proton pump inhibitor . Endo copic 
ablati on ha the advantage of removing the ti sue permanently. 
CONC LUS ION 
astric heterotopia i a rare cause of ga trointestinal bleeding from the 
lower tract in children . Endoscopic evaluation with biop y i fundamen-
tal to diagno i . The type ofti sue pre ent in heterotopic ga tr ic rnuco a 
can vary. as well as the presence of H. Py lori infection, but to date no 
malignant lesions have been discovered in the rectum. Treatment varies 
from proton pump inhibitor and monitoring or removal of the le ion 
via endo copy. 
REFERENCES 
I . Bernadette, M., & Wi ldemore, M. Gastric Heterotopia of the Rectum: a e 
Report. The Internet Journal of Pathology, 5. 2007 
2. Ke temnberg, A., , M., de Lima, E., FT, G., Carrascal, E .. & JL, A. Gas-
Inc heterotopic muco a in the re tum with helicobacter pylori-like organism: 
a rare cause of rectal bleeding. International Journal of Colorectal Oi ease 
1993 (8) :9- 12. . 
3. Sauer, C. G .. Bickson, S. J. , & Borowitz, S. M. Gastric Heterotopia of the 
Rectum. Journal of Pediatr ic Gastroenterology & Nutrition, 2009 50(3 ):329-
6 UWOMJ I 81 :2 I Fall 2012 
333 . 
4. Yincenzi, F .. L, B., Bizzarri , B., Bocce ll ari , F .. Fornaro li , ., & de'Angelas, 
G. (20 I 0). Gastri c heterotopi a in rectum with heli cobacter pylori acti ve in-
fection in a 5-year-old child . Case Report and rev iew of pediatr ic literature. 
XVII National ongreee IGEN P Ab tracts/Di ge ti ve and Liver Di eases. 
20 10(42S): S32 1-S376. 
5. Steele, ., Mu llenix, P., & Martin, M. Heterotopi c Gastri c mucosa of the anus: 
a ca e rep rt and rev iew of the I iterature. Am urg, 2004 ( 70) : 715-719. 
6. Chri tensen, W. , & ternberg, . Adenocariconm a of the upper e ophagu 
ari sing in ectopic gastri c muco a. American Journal of Surgical Pathology, 
1987 ( II ): 397-402. 
FEATURE ARTICLE 
FLAT RATE 





Waterloo 1 London 1 Hamilton I Mississauga I Toronto I North York I Yorkvil le I Whitby I Kingston 1 Ottawa 
UWOMJ I 81 :2 I Fall 2012 7 
FEATURE ARTICLE 
Fight against obesity- is bariatric surgery the 
answer? 
Chanseok (Chris) Rhee (Meds 2013), Yuding Wang (Meds 2013) 
Faculty Reviewer: Dr. Vlad islav Khokhotva , MD, BSc, FRCSC (Department of Surgery, Windsor Regional 
Hospital ) 
0 besity is a medica l state in which an indi vidual has exce ive body fat that causes an increased risk of metabolic derange-ment. It is conventional!) defined as a body mass index (BMI) 
of 30 kglm2 or more. 1 A lthough it may not be con idered a a disease 
by itself. it has been long as ociated with many disea e that are often 
detrimental to hea lth , uch as coronary artery disea e. stroke, diabetes. 
osteoarthriti s. obstructi ve Jeep apnea and more. onsequently, obe ity 
leads to more functional limitations. decreased hea lth-related quality of 
life. and increased utili zation of the healthcare system2 Currently more 
than half of Canadians are reported as overweight (BMI of 25 kg/m1 or 
higher) or obese.3 w ith nearl y a quarter of the population being obese.• 
A more concerning feature is that thi s proporti on ha doubled between 
1980 and today. and it i still increasing.• A sy temic rev iew of arti cles 
publi shed between 1990 and 2009 showed that obesity accounts for ap-
prox imately 0.7% to 2.8% of a country 's total hea lthcare expenditure5 
In addition, the average medical costs pent on an obe e individual were 
approx imate ly 30% gr ater than the costs on an indi idual with normal 
weight.5 In Canada where healthcare costs are uni versa lly covered, the 
total hea lthcare costs for being overwe ight and obe e were estimated to 
be $6.0 billion, which i 4. 1% of the total health expenditure in 2006 6 
A lthough direct comparisons between countries are often diffi cult due 
to different methodologie implemented in mea uring assoc iated med i-
cal costs. higher weight-assoc iated healthcare expenditures in anada 
can be linked to a higher rate of overwe ight and obese indi vidual . In 
Ontario. an obese indi vidual lay an additional burden of about $ 180 
to the healthcare sy tern over one year compared to a normal-weight 
individual adj usted for other health-related factors uch as age. gender, 
ocioeconomic status. and physical acti vity status.7 In add ition, obes ity 
is also assoc iated with other factor that cannot be ea i ly quantified in 
monetary value but nevertheless impact one 's life, such as quality of life 
and leve l ofeducati on.7 
Considering the oc ioeconomic downfal l of obesity, the benefits of 
weight lo are apparent both for indi viduals and soc iety. A obesity 
is clo ely a sociated with lifesty le factors such a poor dietary choic-
es and sedentary lifesty le, the current management of obe ity focu e 
mainly on life ty le intervention.K Weight loss interventions also often 
provide ocia l and p ychologica l upports for improved effectivene s9 
The Counterweight Programme, a weight los programme in primary 
care in the UK which prov ides dietary and phys ica l exerci e scheme 
and also follow-up . is e timated to cost approx imately $370 per indi-
vidual per yearw Thi co t doe not include many extra co ts imposed 
on indi viduals, such a additional food co ts and the co ts of fitne s club 
memberships. 10 A study by Roux and co lleagues inc luded medical, non-
medical. and time per patient costs for weight loss programm es. and 
estimated an indi vidual cost of $3.040 per year.11 Although lifesty le 
interventions may still be cost-effecti ve. they require long-term com-
mitment in both time and energy, with often less-than-ex pected results.? 
everal factors as oc iated with attriti on include decreased body image. 
decreased mental health. lower social support. lower se lf-efficacy. pa-
tient ' higher weight loss expectati on. and co t. 11 A a result. lifesty le 
modification i often combined w ith pharmacotherapy. such as orli tat, 
ibutramine and rimonabant. A lthough effecti ve in we ight reduction, the 
cost of interven tion wi th anti-obes ity medications per quality-adjusted 
life-year (QALY) was e timated to be U $20,000. 13 ln addi ti on. adverse 
effect of medication and high rates of \\eight regain limit the use of 
pharmacotherapy. 13 
urrently. the mo t effective treatment of obes ity is bari atric sur-
gery which result in 30% sustained weight Jo s. compared to 5- 10% 
weight loss \\ ith behavioural and pharmacological intervention.14 Three 
commonly-performed procedures are laparo copic adj u table ga tric 
banding (LAGB). laparoscopic Jeeve gastrectomy (LSG). and Roux-
en-Y gastric bypass ( RYGB). 15 LAG B is a restricti ve procedure where 
a hollow. fl ex ible il icone band i placed di tal to the gastroesophageal 
junction. reducing the stomach capac it) .1" T hi cause early ati ety and 
decreased food intake. consequently resu lting in weight reduction .16 
L SG in vo lves re ecti on of a large porti on of stomach. thus also reduc-
ing the stomach capacity.11 Thi i often a fir t of a two- tage procedure, 
where rerouting of the small intestine is performed to reduce calorie 
ab orpti on. e peciall y the absorpti on of fat .16 RYGB is the most com-
mon procedure performed in orth A merica, compri sing 51% of the 
total bari atric procedures.15 It i a combination of both re trictive and 
malab orptive proced ures and involves creating a small pouch of stom-
ach and rerouting the mall inte tine. The mid-porti on of the jejunum 
i dissected and the distal portion i anastomo ed with the small gastric 
pouch. The prox imal small bowel, connected to the excluded portion of 
the stomach. forms a bi l iopancreati c l imb and i anastomosed with the 
di tal jejunum. Jr, malabsorpti ve tate from bariatric surgery results in 
favourable metabolic eO'ect superi or to those achieved by lifesty le and 
ph~rmacologic~ l intervention .17 Its more substantial and Iong-la ting 
wetght loss eflect place bari atric surgery as an attractive method of 
weight reduction.17 
In Ontario bariatric surgery is currently indicated for patient with 
~M ' · of 40 kg/m2 who are refractory to medical management, includ-
mg lifesty le modification , or individuals \ ith BM I greater or equal to 
3? kg/m1 wtth a maJOr obesity-re lated comorbidity such as hyperten ion, 
~~ a ~e tes, o~ obstructive sleep apnea.18 Currentl y. the only operative bar-
t a~nc techn t_que ?~ing insured in Ontario is the RYGB. although multiple 
pnvate cltntcs oiler the LAB technique. A lthough random ized contro l 
tn a l ~ (RCT) comparing the efficacy of bariatric urge1y w ith standard 
med~ca l management are few, they do point to a signi ficant benefit of 
surgtcal management to decrea e morbidity and mortality.'9.1u The land-
mark Swedt h Obe e ubjccts ( 0 ) tudy (a large prospecti ve multi-
center matched cohort study) howed a significant moltal ity benefit for 
8 UWOMJ I 81 :2 1 Fall 2012 
patient who received bariatri c urge!)' compared to non- urgical con-
entional treatment. 21 ub equent retro pecti ve and pro pective tud-
ie ha e al o shown imilar result .n R T between RYGB and LA B 
have hown the RYGB procedure to have increa ed weight lo , im-
proved re olution of comorbiditi es. lower reoperation rates and better 
patient atisfaction. However, LA BG offers faster recovery time and a 
slightly lower rate ofperioperati ve morta lity and operative morbidityY 
The economic benefi t from a payor ' perspecti ve show that the long 
term ( I 0 years to lifetime) co !-effecti veness of urgery compared to 
non-surgery has been estimated to be U $ 1000-40.000 per Q LY when 
using an incremental co !-utility rati o . 2 ~ A recent y temic rev ie11 and 
analys i for the anadian gency for Drugs and Technologies in Hea lth 
(C DTH) estimated the cost of bariatri c surgery from a hea lth care pay-
or · per pective to be C D$8.000-1 0.000 per QALY over the lifetime 
hori zon in Canada when u ing an incremental co !-utili ty ratioY This 
estimate repre ents clear cost benefi t for surgery compared to medica l 
treatment alone. Furthermore. analy is within subgroups such a obese 
type 2 diabetics incurs even greater hea lth and economic benefi t . Re-
cent meta-analys is evaluating bariatric urgery in patients wi th diabetes 
shows an incremental co !-utility ratio of U $7.000-10.000 per QALY 
and appear to provide a clear hea lth net benefi t and cost aving over 
non-surgical management.16 Moreover. from a payor · per pective. bar-
iatric surgery repre ent an upfront inve tment with ubsequent savings 
pread throughout the patient' lifetim e in terms of both direct and indi-
rect co ts. Co t analysi between common urgica l technique are lack-
ing and at thi time no clear co t benefi t can be a igned to RYGB versu 
LABG. although it is known that LA BG when compared to RYGB of-
fers shorter hospital stay and faster recovery time (measured a time to 
return to work) .23 
Currently. Ontari o performs approx imately 2,000 bari atri c proce-
dures per year funded through the OHIPY There are estimated 300,000 
Ontario re idents that are belie ed to be in need of the procedureY Even 
with recent funding to increa e the number of bariatric procedure pro-
vided by OHIP. there i till a ignificant wai t time for the procedure. 
As clin icians, prevention through life-sty le modifi cations before obesity 
ets in may yet offer the best results. evertheless, bari atri c surgery ha 
clear benefits over con ervati ve and pharmacological treatment . and 
increased funding for bari atri c surgery in addition to continued lifesty le 
modificat ions may warrant max imum long-term co t sav ing to OH IP. 
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INTROD CTION 
Have you ever had a gut fee ling that you were not alone? Before you get 
up to lock the door . consider that our gastrointestinal tract. in parti cular 
the di tal colon. is home to trillions of bacteri a and other microorgan-
i m co llecti ve ly referred to a the microbiome. Fortunately. mo t of the 
microbiota are not harm ful. but instead prov ide phy iological functi ons 
such as digestion and immune system deve lopment. Importantl y. the in-
te tina! microbiome acts as a front line defen e again t potential patho-
gen entering our gut. n important clin ica l example that highl ights thi 
is an in fec tion by a bacterium called Clostridium difficile, which usu-
ally cau e a diarrhea l/colit i syndrome, but in some cases may progress 
into a life-threatening pseudomembranou colitis or a colonic di ten-
sion ca lled tox ic megacolon. Although healthy indi viduals are resistant 
to the ingested spore . cases of C. diffici/e infection (COl) are on the ri se 
because of anti biotic treatments that di srupt the protective microbiota. 1 
To compound thi problem. there are reports of increased incidence and 
mortali ty rates. metronidazole re i tance, and the emergence of hyper-
virulent strain (e.g. Bl API /PCR 027).U This ·epidemic· has fo rced 
us to critica lly eval uate ho'' we manage COl cases. e pecially tak ing 
into consideration the inherent di lemma that ant ibiotic therapy itself is 
causing thi in fection. 
What can be done? The tandard treatment include di continuation 
of the inciti ng antibiotic and adding other antibiotics (metronidazo le. 
vancomyci n). Other additional therapies now include oral bacteri other-
apy/probioti cs, tox in binder . vacc ination. and even performing surgical 
bowel resection.H However. despite additional medical therapy. there 
are some patient ( 15 - 35%) that continue to have chronic recurring 
di sease or a evere pre entation.5 For these pati ents. there has been a 
last ditch protocol that foc u e on replac ing the disrupted m icrobiome 
through a proced ure called feca l microbiota tran plantation (FMT). 
Although th is procedure ha been around fo r over 50 years. it is not a 
mainstream practice even though it ha been found to provide safe. rela-
ti ve ly inexpensive. and rapid relief with potential long term protection. 
This is likely due to di sintere t from pati ents (the ·yuck' factor). phy i-
cians (' natural" approaches wi thout good ev idence tend to be presump-
ti ve ly di smissed), and researcher . In thi arti cle, I will prov ide a fre h 
perspecti ve of FMT and di scuss how it is becoming an increasingly at-
tractive option in light of our improved understanding of the colonic 
microbiome. 
M l CACA ES S CACA 
FMT work on the principle of taking the bacteria in a healthy donor' 
stools and in troducing them into the pati ent's colon in order to restore 
a ' healthy' intestinal microbiota population . Hi tori cally, FMT ha been 
studied and performed in veterinary medicine to treat various di order 
in farm animal s (transfaunation). 2 The fi rst in tance of FMT in human 
was in 1958. "hen a team of phys icians in Co lorado uccessfull y treated 
fo ur pati ent with pseudomembranou coliti s." At the time. three of these 
pati ents had severe li fe threatening post-operati ve coliti that was unre-
spon ive to conventional treatments. In a fin al attempt. the phy icians 
pioneered the FMT procedure and the pati ents miraculou ly recovered 
and ' ere di charged after everal days. It would be much later in 1978 
when C. difficile \vas identi fied to be a cause of ant ibiotic-a ociated 
diarrhealcolit i . which was then fo llowed by the fi r t report of a uccess-
ful FMT in a 0 1 ca e in 198 1.6·7 While FMT wa origina lly performed 
by a crude colonic retention enema of homogenized tool amples ob-
tai ned from closely related or int imate donors. the procedure has been 
refi ned through the 1990 . Nowadays. most studies use tandardi zed do-
nor screening and tool co ll ection. cryoprotectant proces ing and freezer 
storage. and in till ati on with a nasoga tric/na oduodenal tube or guided 
infusion with a colonoscope or upper tract endoscope. 2 ·~·9 However. the 
bas ic engraftment principle applied in 1958 is o simple that there are 
even publi shed ·do-it-yo ur elf" guidelines that rely on eas ily acquired 
item (e.g. kitchen blender. enema bag) and a hea lthy friend. 10 
Today. the mai n indicati on fo r FMT i evere refractory COl or 
chronic disease with a hi story of recurrence and a fai lure of mult iple an-
tibioti c reg imen . Wh ile the evidence is limi ted to case eries and reports 
of chronic COl. recent systemati c reviews ha e found an astounding 
89-92% cli nical re olution of the diarrheal syndrome in over 300 cases 
reported in the literatu re. 2.3· 11 These numbers are encourag ing. but only 
recently has there been interest in conducting a randomi zed controlled 
tri al (F CAL tri al. 2008- ongoing) .12 
One pos ib le objecti on to FMT i the concern fo r afety a there is 
the possibi lity for transmitting in fect ion during the procedure. This is 
a valid concern fo r any attempt to adm inister foreign microbiota as evi-
denced in trial of accharomyces boulardii probioti c treatment in COl 
patient . which had rare report of sepsis and fungemia. 13 urpri singly. 
in a systematic review of 376 case of FMT in ca es of 01 and other in-
di cati ons. there ha not been a report of a major adverse e ent including 
transmitted in fec ti on.3 till. the pos ibi lity ha been taken into consider-
ation by developing protocols such as extensive donor screening in order 
to prevent transmi ion of enteri c pathogen and provide reconstitution 
of ·healthy' microbiota. K 1 ~ 
FMT TREATM ENT FOR OTH ER DISEASES 
lcerati ve co li ti (UC) and Crohn 's di ease are both types of idiopathic 
infl ammatory bowel di ease (I BO) that are poss ible candidates fo r FMT 
treatment becau e of the pos ible pathophy iologic role of the colonic 
bacteria. The fir t report of FMT in UC treatment wa 1989 by Bennet 
and Brinkmann. in whi ch Bennet. who suffered from per i tent C. suc-
cessfully treated him elf. 11 Another report near the arn e time used FMT 
to treat a vari ety of non-COl associated coliti yndrome with ome 
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degree of ucce s. 16 In 2003. there was a landmark study on treating UC. 
which documented a case series of ix patients w ith chronic C who 
underwent FMT. 11 A ll of the patients in the tudy went into remiss ion 
and at 1-1 3 years of follow-up. none of the patients had any ev idence 
of acti ve disea e. indicating that the FMT treatment were as oc iated 
with a lengthy remi ion peri od or poss ible cure. While the ev idence 
is far from definiti ve. it does upport the idea that FMT can be u ed to 
treat other disea e that invo lve the co lonic microbiota. The e disea es 
might include chronic constipati on. obe it)", metabolic syndrome/ insulin 
in en iti vity. irritable bowel syndrome. allergic di ea e. and potentially 
indirect neurop ychiatric alterati ons. 1.-...21 
PERSONALIZED METAGENOM IC MEDICINE 
A lack of rigorou te ting and abundance of biased anecdotal reports 
has made it di fficult for FMT to become wide I) accepted. However. thi s 
may begin to change because of insights drawn from recent microbiome 
research. To tart off. consider the question: what makes each per on 
unique. Of cour e. many would say that it i a combination of genet-
ic. epigenetic. and env ironmental factors. but traditionally few would 
con ider the microbiome as a igni ficant influence. Yet. while geneti c 
sequence vari ation between indi vidual compri e a mini cule fraction 
of our genome. the di fferences in microbiota populati on have been esti-
mated to be as high a -o%.21 Moreover. the microb iome is ea il) ame-
nable to change and is also believed to demon trate d) namic alterations 
with normal age ing. geograph). and environmental changes_l2-H 
Within thi pectrum of variati on \ ithin the populati on. there is the 
possibility that the microbiome may contribute to di ease su ceptibil-
ity. lth ugh many tud ies have experimentally implicated a role of the 
colonic microbiome in variou di ea es. there is a need for populati on 
based studies to establi sh an as oc iation between di fferent microbiota 
populations and pecific disease . To accompli h thi . we can take ad-
vantage of next generation sequencing ( G ) technologies. A lready 
thi year, there are several equencing platform s (e.g. anopore. Mi eq. 
ion PGM-proton) touted to be able to provide extremely rapid and cost-
effecti ve geneti c equencing capabil ity. ing GS. we can realisti cally 
en ision mapping out the human metagenome. which comprises all of 
the microorganism genomes w ithin the microbiome. Currently. there are 
vari ous 1n1t1at1 ve upported by the Intern ati onal Human Microbiome 
Consortium (IHM ) including the N IH Human Microbiome Proj ect 
(HMP) and the European M etagenomics of the Human Intestinal Tract 
proj ect (MetaHIT ). which will perform metagenomic sequencing of 
hundred of indi viduals.z' One of the ground-breaking re ults has been 
the clas i fication ( like blood typing) of individual inte tina! microbi-
omes into 3 major ·enterotype · _22 In addition. at the recent IHM con-
gress. there were presentati ons showing metagenome-wide as oc iati on 
with both metabolic yndrome and type 2 diabetcs.21 A lthough much 
of the work is in the earl y stages. the future of per onali zed medicine 
may someday involve individual metagenomes u ed as a pertinent fac-
tor in diagnosis. di ease management, and determinants of hea lth. In 
thi cenario, FMT could be u ed to treat people with di ea e-a oc iated 
microbiome . 
While FMT began as a last ditch therapy for p eudomembranous 
co litis and Dl. our increa ing understanding of the microbiome may 
mean that FMT has a role in treating other di ca es. Hi tory has s h o\~n a 
lack of intere tin FMT. but the anticipation from metagenomic research 
and the urgency of the CDI epidemic may be the much needed pu h for 
new advances. On an optimi ti c note. Kahn and co lleagues report that 
patients w ith UC are in favour of moving forward w ith FMT, ugge l-
ing that patients may not be as ad verse to the idea as what we might 
think .U• With any luck, we may ec ubstantial development in the year 
to come. 
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ABSTRACT 
Environmental factors, such as so il. ai r and water quality. are we ll 
known to influence population hea lth . With the increasing urbaniza-
ti on of Canada and other countries around the world. more attention i 
nO\\ be ing paid to how the 'bu ilt environment" - all the elements of the 
envi ronment designed by humans - also play a crucial role in human 
health. Thi arti cle brie fl) examines hO\ a few key components of the 
built en ironment contribute to chi ld health. Thought ful placement of 
chools and effort to create safe. wa ll.:able neighbourhoods can increa e 
the number of tudents who '' alk to school instead of rely ing on car . 
Prov iding children and their familie \~ith recreational in frastructure 
promote phy ica l acti vity. Creating farmers' markets in urban cores in-
crea es access to a less expensive source of nutritious food for a city' 
inhabitants. Knowledge about these interaction between urban des ign 
and child health can allow phy ician to prov ide more practi ca l advice to 
their patient about developing a hea lthy l ifesty le within a ci ty. It is also 
a promi ing fie ld for physician advocacy : by offering their expertise to 
in form city planning decisions and persuading city planners to consider 
the health impacts of thei r decisions. physic ians can help make it ea ier 
fo r thei r young patients to li ve a hea lthy, active li festy le. 
THE BUILT ENVIRONMENT AND URBAN IZATION 
When con idering indi vidual patient . we are taught to consider the im-
pact of patients' environments on their health : where and w ith whom 
they l ive, what kind of work they do. etc. It tands to reason that factors 
of a larger environment- uch as a neighbourhood or city - may influ-
ence the health of groups of people l iv ing there. Of pecific intere t is 
the bu ilt envi ronment (BE) - all f the elements of the envi ronment 
de igned by human - including the land-u e zoning of a neighbourhood. 
road layout . access to hop and facil iti e • and the pre ence or ab ence 
of side\ alk . A growing body of research illu trate that BE de ign in 
urban and uburban areas can have a ignifi cant impact on the hea lth or 
people li ving in the e area . This arti cle endeavour to give a practi ca l 
overview of the influence of BE on hea lth, with a spec ific focus on how 
BE can influence child health, acti vity leve ls and development. 
Where people li ve in anada has changed dramatica lly since World War 
II and the ubsequent boom of indu try, with an increased proporti on 
of the population moving toward urban areas. urrently, 68% of the 
anadian population l ives in metropolitan areas and this fi gure contin-
ue to increase annually. 1 The development of suffi cient hou ing and 
in frastructure for the rapidly growing number of city dwe llers often re-
sults in urban prawl. The low-den ity housing and partitioned land u e 
common to uburban area may now be contributing to chronic health 
problem .1 At least four main threats of prawlto population health have 
been identified: phy ical inacti vity, poor air quality, more motor vehicle 
coll i ion due to reliance on cars, and mental hea lth issue .3 Mitigating 
such health effect requires an understanding of the interplay of city 
design and human hea lth fo llowed by appropriate urban planning. 
THE C RRENT STATE OF CH ILD HEALTH IN CANA DA 
The most recent estimate ugge t that 26% of Canadian children are 
overweight and 8% are obe e. The percentage of children that are over-
we ight or obe e have doubled and tripled. re pecti ve ly. over the past 25 
) ear and re earch indicate that the e unhealthy body we ights often 
per ist into adu lthood.~ To curb thi trend, public education ha focused 
on the importance of children eating five or more dail) erving of fruit 
and vegetable and engaging in regular phy ical acti vi ty. However. the 
role of a child 's neighbourhood environment in influencing their phy i-
ca l acti vity and overall health is often not con idered. Finding ways to 
create an envi ronment that encourage phys ica l acti ity is a noveL pop-
ulation-ba ed approach to help curb the trend toward childhood over-
we ight/abe ity as \\ ell as the presence of ·adult· di eases in children 
(e.g .. type 2 diabete mell itu ). 
COMM NITY PLANNING FOR H EALTH Y LIFESTYLES 
The choof ommute 
Walking to school wa pre iously a taple daily acti v ity for mo t chil-
dren. Howe er, thi ha been eroded by a trend lO\vard bui lding larger 
centralized schools to which children must be bused, increa ed parental 
fear over child safety and the construction of les ·walkable' neighbour-
hoods. ot surpri ingl). the most important factor influencing whether 
or not children commute to chool in a phys ica lly acti ve \v ay i prox im-
ity . Specifi ca ll y. if children li ve :S 800 m from their chool they are 5-1 0 
time more li ke !) to com mute acti, ely to chool than if they li ve farther 
away.' 
More ubtle factor ha e al o been identi fied that make a neighbourhood 
·walkable. · namely ' hat' e assoc iate with ·older · neighbourhood - a 
grid system layout with lots of connections between road , high popula-
tion den ity and a vari ety of land u es including hou ing, shops, ser-
vice , and recreational fac ilities. Converse ly, most suburban housing 
developments are de igned in uch a ' ay that walking i unappealing: 
streets are often convoluted in their layout. connection to stores and 
re taurants are limited, and there is a low population-den ity. The e car-
ori ented neighbourhoods di courage physical! acti e tran port. ' On the 
contrary. children and adolc cents \vho li ve in ·walkable' neighbour-
hood not only walk to school more often but are also more like! to be 
phy ica lly acti ve outside of school hours. 1 
Both the rea l and perce ived danger of a neighbourhood are critica l fac-
tors in parents' deci ion abou t allowing their children to walk to school 
a1. d other local ~estin ation s. imilarly, older adolescents - e pecially 
g1~l - are more likely to be active in their neighbourhood if they per-
Ce ive them to be afe. 1 Thi may explain why male are more likely 
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to acti ve ly commute to chool than gi rls- they tend to perceive thei r 
neighbourhoods a safer. reating afc neighbourhoods in which resi-
dent perce ive them as such is key to encou raging phy ica l activi ty." 
Recreational Facilities 
The avai labi l ity of recreational faci l ities (parks, play ing fi elds, poo ls, 
etc.) also play a role in how active chi ldren arc in a given environment. 
A survey study done in London, Ontari o found that after controll ing 
for season and demographic factor , youth who have two or more rec-
reationa l facilities in their neighbourhood engage in an average of 17 
minute more daily phy ica l acti vity than thei r comparab le peer who 
ha e fe1 er local facilitie .7 Trails for 11 alking and cyc ling can also help 
to promote physical act i ity. One Texa tudy found a 1.5 time greater 
odds of walki ng for a minimum of half an hour at least once a week 
among people who perceived themselves a li ving close to a trai l. ~ Thi 
is a modest fi nding. but does show a potential role of trails a one small 
tep in e tablishing a culture of phy ical activity for fami l ies. To max i-
mize trail usage. city planners des igning trail routes should note that trail 
segment with mixed iew of urban and natural landscapes a opposed 
to onl) natural view experienced 39°o higher trail traffic.K This further 
touts the hea lth benefit of mixed land u e mentioned in the studies on 
1\alkable neighbourhood .5 
Access to Nutritious Food 
Much like recreational opportunitie , acces to a source of nutritious 
food can have a positive impact on a child 's hea lth. Unfortunately, dis-
parities in food access related to ocio-economic factors have been we ll 
documented in everal studies in both the U and UK 9 Recent tudies 
have examined whether neighbourhood characteri stics such as proxim-
ity to a grocery store serve to lessen such di parity. One Toronto study 
found that only I% of variati on in food security and even less of the 
variation in severe food insecurity could be attributed to one's neigh-
bourhood of residence. This effect actually di appeared completely after 
accounting for covariate uch as income, number of dependent children 
and status as a recen t immigrant. leading the researchers to conclude 
··we found no e idence that geographic food accessibility mitigates the 
effect of financial con traints on household food sec uri ty. "~ 
Converse ly. a different study examined the effects that the creation of 
a farmer 's market in a food desert - a di trict wi th little or no access to 
healthy foods - in London. Ontario had on the price and avai lability of 
health) food . The researcher found that the market improved acce s to 
fresh food uch as broccoli and green grape and all owed for hundreds 
of dollar in potential annual saving for families.10 Such savings cou ld 
help to reduce the financial barrier to a healthy diet like tho e noted in 
the Toronto tudy. allowing paren t to afford hea lthier food for their 
children. 
W HY SHOULD PH YSICIANS CA RE? 
Similarly to how overweight/abe e children become overweight/abe e 
adults, phys ica lly acti ve teens are much more likely to be acti ve as 
adults. 11 By tak ing steps to ensure that our children and adolescent pa-
tients are acti ve and healthy in their younger year we are setting the 
foundation for hea lthy l iving in the year to come. 
Preventing or delay ing chronic di ease in our children is one of the 
most efficient way to help both our community' hea lth and our over-
burdened health care system. Intervention to change the BE may serve 
as a powerfu l tool in achiev ing thi goal. Notably. changing the BE is 
less rel iant on evoki ng specific behaviou ral change within individual 
patients- a difficu lt task to which any doctor can atte t. As Dr. Leon-
ard Syme, an epidemio logist at C Berkeley's chool of Publ ic Health 
points out. "Changing individual behaviours in iso lation may be more 
FEATURE ARTICLE 
difficult than modifying the environment that faci l itates and promote 
them" 2 
W H ERE DO WE GO FROM HERE? 
For doctors to succes fu lly harnc s urban planning a a new too l in pa-
tient care, there are two vital goal : 
I . co llaboration w ith other profes ionals uch as politician , city plan-
ners, public hea lth profcs ionals and teachers 
2. advocacy for population health a a major factor in ci ty planning 
decisions 
For example. phy ician cou ld join 11 ith school board officia ls and other 
community partner in creating l'valk-to-school campaigns. This might 
involve having pamphlets and other literature availab le in their offices 
for parents, a well a peaking to thei r young pa tient about how walk-
ing to schoo l can help keep them hea lthy. ity plann ing advocacy could 
follo11 the lead of the campaign that banned smoking in public place , in 
l>hich physicians played a crucia l role. Hopefu lly as phy ician become 
more informed about the impact urban de ign can have on their patients. 
similar advocacy gain can be made in the field of ci t) planning. 
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A BSTRACT 
Background ontext: M edical schoo l. and parti cul arly clerk hip. is 
tre ful. L ittle re earch ex i t regarding the u e of sub tance and po-
tentially addicti ve beha iours to cope with medical choo l stressor . 
uch coping strategie pre ent an ethi ca l i sue a the) may hinder aca-
demic or clin ical performance. 
Objecrive: To compare the use of five maladapti ve coping behav iours -
caffe ine. alcohol. gambl ing. toba co. and drugs- bet\\ een pre-clerk hip 
and clerkship tudents. 
Methods: A cro - ectional study wa perform ed u ing an anonymous 
online survey di tributed to all medica l student at the chulich choo l 
of M ed icine & Dentistry. Data wa analysed using Student t-test to 
compare the mean number of coping behav iour u ed. Subgroup ana ly-
e using Mid-P Exact chi- quared tests were conducted to examine the 
prevalence of each. 
Result : The total num ber of maladapti ve behav iour was not stati sti-
cally di fferent bet' een the pre-clerkship and clerkship years. ubgroup 
analyse indicated no signi ficant di fference in the u e of any one behav-
iour. while there were trends towards signi ficance in the preva lence of 
non-pre cript ion drug use. 
onclusion: The study lacked stati ti ca l power to how an increase in 
the total u e of maladaptive coping behav iours between pre-clerkship 
and clerk hip student . There were al o no ignifi cant change in the 
u e of any specific behaviour. Future studies \\ Ould benefi t from a larger 
ample ize and longitudinal study de ign. 
INTROD CTION 
In health l iterature. the term ·stre · igni fie a negati ve experience pro-
duced from the interaction between the person and hi or her en iron-
ment, re ulting in psycholog ica l. physica l and behav ioural con equenc-
e .1-1 According to the A meri can P ycholog ica l A oc iati on (A P ). stress 
has become a growing concern because of its phy ica l and psychologica l 
consequences.\ People employ vari ous coping trategies in an attempt to 
manage strcs . Coping can be defined as behav ioural effort employed 
to manage. reduce. or control stres .1' In a 2009 survey performed by 
A PA, 81 % of th ose surveyed bel ieved they were managing their stre s 
we ll : however. many of them were using maladapti ve trateg ie such a 
tobacco, gambling. or drinking alcohol a coping mechanisms.6 
everal tudie world wide have demonstrated that being in medica l 
choo l i one of the most tress ful experi ences due to the volume of in-
formation. long hours of tudy. and I im ited time for se l f and/or family. 7 
M oreover. the clerk hip period is particularly tre fu l since the student 
transition from didacti c-based learning to direct patient care.x Overall. 
the e stre sors can cau e a detrimental effect on academic performance. 
phys ica l health. and psychologica l '' ell-being. ultimately influencing 
performance. not only a student . but also later as careg ive r .9• 111 De-
spite the potential importance of coping strateg ie • few in vestigators 
have stud ied how phy ician cope w ith tre . Of the e. mo t report 
po iti ve coping beha iours. uch a seeking counse lling. meditation. 
and exercising. 7 11 However. no recent l iterature ha reported maladap-
ti ve coping behaviour a a way to manage stre sa a medica l student. 
It was hypothesized that there \\Ould be an increase in use of potentially 
add ictive behaviour a coping mechanisms in medical chool from pre-
clerkship to the clerkship year . pecifically. the pre ence and preva-
lence of the fo liO\\ ing maladaptive beha iours '' ere examined: caffeine. 
alcohol. gambling. tobacco. and non-pre cripti on drug u e. The aim of 
thi s study i to prov ide a deeper under tanding of the maladapti ve cop-
ing mechanisms that medica l tudent u e. 
METHODS 
M edica l student from the clas es of 20 14. 20 13. 20 12. and 20 II at the 
chulich chool of Medici ne & Denti try '' ere asked. v ia electronic-
mail. to complete an online un e) of thei r u e of caffe ine. alcohol. gam-
bling. tobacco. and drug . Participati on in this tudy wa voluntaf) and 
anon) mous. Thi study ' as appro\ ed b) the chulich research ethics 
board (R - B con ent # 176 13E). 
For each of the fi e maladapti ve behaviour . the parti cipant wa 
a ked to i) report the frequency of use in the last six months, ii ) gauge 
his or her dependence on each coping mechani sm. A well. questi on 
regarding whether the student fe lt tho e coping mechani m had ever 
influenced their perfo rmance in ocial, academic. or prote sional situ-
ations \\ ere included . The data were co llected in Januaf) 20 11. , hich 
gave fi r t year clerk an opportun ity to experi ence the tre ors of clerk-
hip for fi ve month before re ponding. 
A cr s -secti onal analy i of the 242 re pondent wa conducted 
with student di vided into pre-clerkship (20 14 and 20 13) and clerk hip 
(20 12 and 20 II ) year . ince all urve data were de-identified. only 
group analyses were conducted. The difference between the total num-
ber of maladapti ve coping mechanism employed by pre-clerkship and 
lerk hip student were compared and analysed u ing t\\ O-tailed tudent 
t-te ts. In addition, subgroup analy es were performed using two-tailed 
Mid-P Exact chi- quarcd te t to identify difference bet\\ een pre-clerk-
hip and clerk hip group with respect to the pre alence of each. 
RE ULTSAND DISC SION 
umerous studie have discu ed the stresses and pres ure that tudents 
face du:in_g the i~ medical training. 12· 13 everal have at o suggested that 
clerkship 1 part icularly stres ful for students.x Most tudie of the meth-
ods used by medica l studen t to cope with these tresse have focu ed on 
engagement and disengagement or acti ve and avoidance mechanisms. 7• 
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Table I. Subgroup analyse of the five maladaptive behav iour in Pre-Clerkship and Clerkship tudents. 




P-va lue Total(%) 
N=242 
Gender 
Male 71 (47.7) 
Female 78 (52.3) 
Caffeine 
U ed in last 6 months 141 (94.6) 
Mean weekly' 7.67 [6.68] 
Dependence 53 (3 7.6) 
Coping 91 (64.5) 
Alcohol 
Used in last 6 month 141 (94.6) 
Mean weekly 1 4.20 [3.97] 
Dependence 2 ( 1.4) 
Coping 21 ( 14.9) 
Influence on performance 43 (30.5) 
Gambling 
U ed in last 6 months 26( 17.4) 
Mean monthly' do e 1.60 [3 .82] 
Dependence 0 (0.0) 
Coping 0 (0.0) 
Influence on performance 0 (0.0) 
Tobacco 
Used in last 6 months 13 (8 .7) 
Mean monthly' dose 0.3 1 [0.86] 
Dependence I (7.7) 
Coping 2( 15.4) 
Drugs 
Used in last 6 months 29 (19.5) 
Mean monthly1 dose 0.89 [1 .79] 
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1.01 [2 .14] 
2 ( 14.3) 
4 (28.6) 
28 (30.1) 
1.4 1 (2 .05] 
I (3 .6) 








I 08 ( 44.6) 
134 (55.4) 
23 1 (95.4) 
86 (37.3) 
135 (55.8) 








27 ( 11.2) 
3( 11.1) 




Influence on performance 7 (24. 1) 7 (25.0) 14 (24.6) 
1Mean use of each behaviour reported weekly or monthly exc luding responses where survey participant denied use with in the last 6 months. Values 
reported as: mean [standard dev iation]. 
14 This study is one of the first to directly examine the u e of substances 
and potentially addictive behaviours as method of coping with stress. 
Specifically, we examined the use of caffeine, gambling, tobacco, and 
drug use in medical students across the four years of chu lich chool of 
Medicine and Dentistry (Table 1 ). 
The total prevalence of maladaptive coping behaviours (caffeine, 
gambling, tobacco, and drug use) in the clerk hip year and the pre-
clerkship years wa not significantly different (P=0.227) with reported 
average number of inappropriate strategies used of 2.49 and 2.35. re-
spectively. While this did not support the hypothesis, it may be second-
ary to the small sample size. The prevalence of these behav iours is dis-
played by group in Figure 1. Over 80% of the tudent reported the use 










0 1 2 3 4 5 
• Pre-Clerkship 1.3% 6.0% 59.1% 24 .8% 7.4% 1.3% 
Clerkship 0.0% 8 .6% 52.7% 22.6% 12.9% 3.2% 
Number of Coping Behaviours Used 
Figure I. Bar graph sho\\ ing number of maladapti e cop ing behav iours in pre-clerk hip and cle rk hip students. The total number of the five coping 
mechanisms -<:affeine. alcohol. gambling. tobacco and drugs (x-ax is) - wi th frequency of use in percent (y-a\ is) i depicted as bar graphs for the pre-
clerk hip and clerk hip group . 
of two or three maladapti ve behaviours. The most commonly reported 
behaviour wa caffeine u e (95.4%). followed by alcohol use (93 .8%). 
lntere tingly. 23.6% of medical students reported the use of drugs in the 
past six months. Additionally. 27.8% of students who reported alcohol 
use and 24.6% of students who reported drug use al o indicated that 
it ha had a negati ve influence on their performance or attendance at 
chool or in the clinic and/or ho pital setting. 
Subgroup analyses were per form ed for each coping mechanism 
look ing at prevalence. The frequency of u e. dependence. u c of the 
behaviour to cope wi th stre , and in nuence on per formance are pre-
ented in Tab le I for interest, but not stati ti ca l analys is. In ubgroup 
analy is, no stati stical difference was found between the clerkship and 
pre-clerkship groups. However, there is a trend toward significance in 
the preva lence of non-pre cripti on drug usc (P=0.062). This uggest 
there may be a greater amount of drug use in the clerkship years a a 
cop ing strategy. Si nce the survey defined drugs to be ·mood-altering 
ub tance • well a ·pharm ace utica ls used not a directed ', it would 
be of intere t to in vestigate the pecific drug that are being consumed 
in order to better categorize the level and type of dependence. pec ifi-
ca lly, future study may differentiate illicit drugs like marijuana. cocaine. 
and heroin from the unintended use ofGravol for sleep induction, which 
have very di fferent soc ial perceptions. 
A lthough thi s is a novel study looking at the students of one Cana-
dian medica l school and their maladapti ve behaviour . it does have two 
main drawbacks: the sample size and the type of tudy. The sample size 
of thi s study was limited to the 242 medical student who completed the 
voluntary survey. Consequentl y. thi s study ha many trends toward s ig-
nificance. yet only a few stati ti ca lly signifi cant observations. For future 
studies. more than one Canadian med ica l choo l shou ld be enrolled to 
achieve a greater number of participants. In add ition. thi s study wa a 
cro - ecti onal tudy of a group of pre-clerk hip and clerkship tudents. 
rather than a longi tudinal stud) of the same cia s during the tran it ion to 
clerkship. Unlike a longitudinal study. any differences observed could 
be a blend of cohort effects and true change in the outcome over time. 
These preliminary result should be further explored u ing a longitudi-
nal study to foliO\\ the same cohort of med ica l tudents through their 
pre-clerkship and clerk hip years. 
While there '' a no signi ficant difference found between the pre-
clerk hip and clerk hip group . all of the urvey respondents were medi-
ca l tudents. and a such '~ e re expo ed to the tress of med ical educa-
ti on in general. similar tudy of student in other profe sional degree 
program or post- econdary ed ucation may be prudent; this would al low 
for e. ami nation of the effect of exposure to medical school stresses on 
cop ing. ' ithout the di tinction of exposure to clerk hip. Further study 
might be comp licated by the diffi culti es of a igning an appropriately 
matched cohort. For example. medica l students are typically older than 
students enrolled in other undergraduate programs. 
In conclu ion, thi s tud did not find ignificant diA .. erences in the av-
erage number of maladapti ve coping behav iours used by pre-clerkship 
and clerkship medica l tudents. Further analy is l ikewi e did not dem-
on trate significant difference in the prevalence of caffe ine. alcohol. 
gambling, tobacco. and non-prescripti on drug u e as a coping trategy. 
There were. however, trend toward signifi cance in the greater use of 
non-prescription drugs by clerkship tudents. This tudy annot con-
clude that the elevated tre s of clerkship years in medical schoo l i 
correlated with maladapti ve behaviour . Con ·cquent ly. these re ult 
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illu trate the need for further tudy. focu ing particularly on the u e 
of non-pre cription drug . Future study may benefit from longi tudinal 
de ign and greater ample ize, as well a the inclusion of non-medica l 
tudents. With more information. it may be va luable to consider imple-
menting program to help student cope with stres in a more producti ve 
and positi ve manner. 
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Radiofrequency ablation (RFA) in the treatment of 
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BACKC RO ND AN D HISTORY 
The incidence of primary li ver cancer in Canada ha been stead ily in-
crea ing. ha ing more than doubled since 1980.1 This increa e is par-
tially attributed to the increasing rate of hepatitis C infection. alcoho l 
abuse. and immigration from developing countries where the incidence 
of hepatocellular carcinoma (HCC) i much greater.U The li ver i al o 
the mo t common site of metastase . e pecially from co lorectal cancer 3 
The best treatment option for HCC and liver-only metastases is urgical 
re ection. however, only I 0- 15% of patient are uitable candidate for 
thi procedure:1 As such a small proportion of patients are eligible for 
surgical resection or ab le to receive a li ver for transplantation, a number 
of ditrerent modal ities have been explored as treatmen t options, includ-
ing. but not limited to. rad io frequency ablation (RF ). rad iotherapy. per-
cutaneous ethanol injection. and tran arterial chemoemboli zation. RFA 
is afe. and a oc iated with fewer ide-effect and shorter ho pi tal tays 
compared to urgical re ecti on.1 
The u e of heat in medicine date back to antiqui ty when various 
ancient ocietie from the Greeks to the hinese knew of the u e of cau-
tery to top bleeding. In 189 1. Jacque -Arsene d. Arsonoval found that 
alternating current at 20kHz or higher can heat ti s ue in the human body 
without muscle excitati on6 early four decade later, Harvey ushing 
and William T Bovie developed the Bovie knife. a small knife where an 
alternating current was pas ed o that it can burn through or cauteri ze 
the ti s uc on contact. 7 In the earl y 1990 ' radiofrcquency electrocautery 
wa further explored. and modified into what is now RFA as a way of 
treating mall liver tumours.'' 
EVAL ATION AN D CONTRA ! DICATIONS 
Prior to operati on. the nature of the li ver tumour are carefully eva luated 
by abdom inal CT or MR imaging. Tumour larger than Scm or number-
ing greater than five are contraindicati on for treatment by RF due to 
the difficul ty in ablating a tumour of uch a i ze . ~ Their location relati ve 
to pertinent tructure uch as other visceral organs, bile ducts and ve -
se l are noted as it comp licates the procedure. It is difficu lt to completely 
ab late tumour near ves el due to the coo ling effect of the blood now. 
Ab lation also poses a risk for causing necroti c damage to nearby organs 
such as the bowel or diaphragm. as we ll as cau ing biliary obstruction 
and damage. A lthough the majority of RFA in the li ve r are performed on 
primary IIC tumou rs or co lorectal meta tases, it i al o performed on 
metastases from other area such as the pancreas and breast. De pitc the 
advantage pre ented by RFA. urgical re ection i till considered the 
go ld tandard, and hould be con idered if the patient is found to be el i-
gible on eva luation. However. thi s i rapidly changing as more advanced 
RFA techniques emerge. Ex tra-hepati c in vo lvement is also a relati e 
contraindicati on for RFA . Hematol ogy tests for coagu lopathies are per-
formed a the procedure may require mu ltiple inserti on of large gauge 
needle as we ll as poses a ri k of complicati ons re ulting in surgery8 
RA DIOFREQ ENCY A BLATION 
There are three primary approaches to performing an RFA: percutane-
ou . Japaro copic. and open. Percutaneous RF is above all the preferred 
approach a it i the least inva ive. require only consc ious edation, 
inexpensiYe. ha minimal ide effects. and the patient can be di charged 
"ithin 24 hour . Earlier percutaneou procedure '' ere limited to tho e 
\vith a few mall tumour in the periphel) and a\ ay from the diaphragm. 
However. with adYanced technique uch a h) drodis ection these chal-
lenging lesions can al o be treated. Advanced ultrasound and 30 ultra-
sound. coupled'' ith CT canning has helped to isuali e the entire li ver 
to help in aba lati on 9 
There are only a few centre ,_,here interventional radiology i not 
avai lab le that perform laparoscopic RF . and thi is u uall) used in con-
juction with li ver resection. or other debulking surgeri es. Thi approach 
i generall) used on patient '' ith cen trall) located tumour . tumour 
located near large blood ve el _ and those wi th minimal abdominal 
procedures performed in the past. s it i a more inva ive approach. it 
i le cost-effecti ve. a sociated '' ith more complicati ons. and requires 
a longer ho pital ta) . It is also much more technically challenging to 
perform. as the angle of approach of the radiofrequency need le is re-
tri cted.111 
The open approach is generall) reserved for those patients ' ith mul-
tiple large tum our ranging from 4-Scm or involves a large ves el. An 
pen approach allo'' for the temporary occlu ion of the hepati c artel)' 
and portal vei n. knO\\ n a a Pringle maneu er. which minimi ze blood 
now. the cooling effect from the blood ft ow is minimized, the larger 
tumour arc more like!) to be completely ab lated. If the patient al o 
present with a separate tumour that cannot undergo RFA but i uitable 
to be resected. it can be surgicall ) removed during the ame operation. 
The di advantage of thi approach are similar to tho e of ther open 
surgerie as it i more expen ive. requires general anesthe ia. a longer 
hospita l stay and is a ociatcd wi th increased morbidit and mortal ity.4 
Prior to the operation. the ite of entry is locally anesthetized and 
the patient i gi en an IV edative. General ane thesia is indicated for 
percutaneous RFA when po r tolerance is ex pected with local ane thetic 
alone as in cases of drug abu e or cancer patients, or if the operation is 
expected to Ia t more than 3 hours.M 
The RFA needle is guided toward the tumour by ultrasonograph . 
The aim of the procedure i to ablate the entirety of the tumour as we ll 
a a 1-2cm tumour-free margin .11 However. ultra ounography is unable 
to accurate ly how the extent of the ab lation, and tumour margin tend 
to be obscured by the ablative action. o care mu t be taken to en ure 
complete ab lation. 12 Tumours are u ually treated from the deepest to the 
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most superficial as the ab lated area may obscure ultrasonographic v isu-
alization of deeper ti sue. Sing le ablations are u ually suitable for small 
tumours mailer than 3cm, but for larger tumours, multiple overl apping 
ablations should be considered. The RF need le remains acti ve during 
removal from the tumour to prevent eed ing of malignant ti ue along 
hea lthy li ver tissue. Po !-operati ve ly pati ent is g iven an antiemeti c and 
analgesics to control the nausea and pain often a oc iated with RFA." 
POST-OP AND COMPLICATIONS 
A n abdominal CT is performed one month after the operati on to as-
sess the extent of the tumour ab lati on. wait ing period is nece sary as 
ablati on cause a temporary hyperemic ring to appear on CT that may 
ob cure any rema ining tumour areas. A rter thi a repeat CT is performed 
routinely to look for poss ible intra or extrahepati c tumour recurrence. I f 
an intrahepatic tumour recurrence i found . the pati ent can undergo per-
cutaneous RFA again . Percutaneou RF can be repeated as many time 
as necessary in contrast to the other RF approaches which are often 
one-time procedure . I f the recurrence i large or complicated. th en oth-
er treatment modalitie may be con idered uch as chemoembolizati on.• 
portion of patients may ex peri ence flu-like y mptoms 3-5 days 
post-operation that is also described in patient of imilar procedures 
such a chemoembolization and Cf) oablati on. The fever may be accom-
panied by fati gue and night \\eat Ia ting anywhere from 1-3 week . 
upporti e care is recomm ended, but if the fever last longer than 5 
day , the patient i asses ed for possibl e sep i . RFA is generally con-
sidered safe, but orne seriou compli cat ions have been reported such as 
pleural effu ions. intraperitoneal bleeding. and burns to the diaphragm 
and colon .K 
FUTURE DIRECTIONS 
A major hurdle in RFA i the di fficulty in fully ab lati ng large tumours. 
Currently, a ing le ab lation can reach a ti ue vo lume 2-3cm in diam-
eter, but multiple ablations in the same area or reducing hepatic vascu-
lar inflow can increase the effective ablated volume. ewer and more 
effective needles and radiofrequency generator have been developed 
since the advent of RFA to increa e ablation volume and further im-
provements continue to be re earched. ne such innovation being inve -
tigated is the use of pul ed current RFA as oppo ed to con tant current 
RFA where the former wa found to produce a larger volume of ti ssue 
necro is. 13 Other energy ource such as Microwave technology are also 
being u ed for ablation. 
The benefits of the minimally -inva i e nature of percutaneou RFA 
are obvious in the treatment of mall tumour in early stage I-ICC. How-
ever. in a situation ' here a patient wou ld be uitable for both RFA and 
surgical resection, the latter wou ld be the tandard of care. but very fev 
patients are candidate for surg ical re ection due to pre-ex isting com-
plex li ver di ease. If a large randomi zed control tri al can show that be t 
curative treatment between RFA, urg ica l re ecti on. and I i ver transplan-
tation in early HCC i RFA. then it may become the new standard of care 
due to its cost-effectiveness and minimal complication . 
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I NTRODUCTION 
Colono copy i an endoscopic too l used for the visuali zation and biop y 
of the large inte tine ' ith important appli cati on in the in esti gati on of 
co lorectal cancers. Colono cop) has been u ed to diagno e co lorectal 
cancer ince the late nineteen six ties. and is currently the gold standard . 
Ho,,e er. colonoscopy i not wi thout hortcoming and attempt have 
been made to improve th is technique. Thi paper' i ll briefly re\ iew the 
history of colonoscopy. its cu rrent applications. and the limitati ons of 
colono copy for the diagnosis and creening of co lon cancer. It \viii 
Ia tl) examine innovations in co lono copy and the advantage the) 
might offer. 
HISTORY OF' COLONOSCOPY 
Dr. William Wolff. and Dr. Hiromi hinya. pioneered the development 
of the co lono cope.1 Their invention. in 1969. wa an advance over the 
barium enema and the fl ex ible sigmoidoscope because it allowed for the 
vi ualization and remo al of polyps from the entire large intestine.1 2 
Wolff and hin) a advocated for thei r invention and publi hed much of 
the early ev idence needed to overcome keptici m about the device' 
afety and efficacy. 2 Once the ba ic technology of the co lonoscopc had 
been accepted. the dev ice lent it elf to adaptations that have bettered it 
performance. and broadened its appli cation . The u e of co lono copy 
to creen and diagno e co lorectal cancer continue to ri se .1 • ' ltimatc-
ly. the significance of the test has been to permit an understanding of 
colorectal cancer through the co llection of biop ie . and to lower mortal-
ity through screening and diagno is. 6 7 
COLORECTAL CANCER AND COLO NO COPY: C RRENT 
I NDICATIONS 
olorectal cancer is the second mo t common ca u e of death from can-
cer among both anadian men and women: an estimated 22 000 ca cs 
were diagno ed in 20 11.x Mo t co lon cancers begin as mall protruding 
growths called polyp . The chance that a polyp' ill deve lop into cancer 
varie from 2% in lesions under 1.5 em in diameter to approximately 
I 0% in le ion over 2.5 em in diameter. 'J Premalignant polyp, are esti-
mated to progres over a peri od of approx imately I 0 years.111 Earl y form 
of colorectal cancer are amenable to treatment. If the di ea e is detected 
in a local stage. the 5 year surviva l rate is 90 perccnt.6 However. if the 
cancer has spread reg ionally the survival rate is 68%, and if disease ha 
metasta ized the urv ival rate i only I 0%-" nfortunately. most case 
of co lon cancer are a ymptomatic until advanced tage of the di ea e. 11 
Given the long progression time of thi form of cancer and the high 
ucce rate of early treatment, it i not urpri ing that creening pro-
gram for colorectal cancer have been able to how sub tantial urvival 
benefi ts.'' Colonoscopy has played an important role in these programs. 
The current guidelines on the screening of co lorectal cancer ac-
knowledge that a wide range of acceptable options exist. For indi -
viduals of average ri sk over 50 years of age, the recommendation is 
co lonoscop) every ten year. fl exi ble sigmoido copy (FI G) every five 
year . or annual fecal occult blood te ting (FOBT).6 Colono copy is the 
recommended creening te t for most individual with increa ed ri sk 
for co lorecta l cancer .6 ddi ti onall). colono cop) i the recommended 
follow-up procedure for po itive FOBT and F IG. 
A a creening te t. colono cop) ha t\>o di tinct advantage com-
pared to other mean of creening for colorectal cancer. One advantage 
i that it can be u ed to remove pol) ps from the entire length of the 
co lon. which reduce the incidence of colorectal cancer.6· 9 Furthermore, 
co lonoscopy provide biopsy ample '' hich creen for patient that are 
at a higher ri k of develop ing cancer in the future: the e patients will 
benefit from more frequent creening.6 12 
LIMITATIONS OF' COLO 0 COPY 
While co lon cancer i a erious di ea e. the lifetime prevalence is ap-
proximate!) 6°o in orth merica: 94°o of patient ' ho are creened 
"ith co lono cop) do not benefit from undergoing the procedure. 11 
Therefore. despite the obvious potential for colono copy to prevent 
colorectal cancer. it i neces ary to examine the di comfort and ri sk that 
patient are expo ed to. the limitati ons in sensiti vity. and the cost of 
co lonoscopy. 
Patients undergoing co lono cop) require moderate edation and di-
etary bowel preparation. 11 The preparation involve con uming a fluid 
diet and Pi co- ala\.. a mi.'. of o moti ca lly acti ve and laxati ve ub tances. 
ot all patients manage to complete the entire preparation a required 
and thi can decrease te t en iti vit) a polyps may be mis ed in tool. 13 
In addition. the tc t i uncomfortable and patient req uire mild sedation 
at the minimum. Despite celation. the test is perce ived negati ve l y. 1 .~ 
a con equence, compliance ha ubstantially hindered the effective-
nc s of co lona copy ba eel screening programs.1; Furthermore. a general 
anesthetic is often required for patients who fee l too much pain or dis-
comfort on mild edation alone. This ubstantially increases the cost. 11 
A we ll as di comfort to the patient. undergoing colonoscopy also 
carrie the ri k of complication . The mo t severe complication , bo' el 
perforation and bleed ing. are estimated to occur approximate!) 1.64 and 
0.85 times, re pecti vely. per thou and test .16 The rate of complication 
has al o been reported to ri e ub tanti ally following polypectomy. to 
approx imately 8 per one thousand test .17 
When evaluating the te t performance of standard colonoscopy. pol-
yps are c timated to be mi sed at a rate of27% overa ll and 6% for ade-
noma larger than I cm. 1x c lonic cancer i also n::ported to be mi eel at 
a rate of 5% with standard co lonoscopy. 1x However, there is ub tantial 
va ri ation in test characteri tic based on the operator. 1 ~ 
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From a health care y tern perspecti ve, co lono copy has significant fa-
cility and equipment costs and require technica l experti se to be per-
formed effecti ve ly. In Canada. it i e timated to co t $352 per diagno ti c 
procedure, or $467 per therapeutic procedure, when overhead cost and 
the phys ician's fee are included in thee timate. 20 
The limitations of colonoscopy must be con idered in the contex t of 
the primary alternati ves. FSIG is an endoscopi c technique done with 
minimal bowel preparation and without edation. However. FSIG only 
allow the only distal third of the large bowel to be vi uali zed, making 
itl es sensiti ve than colono copy.r' The FOBT i a less invas ive, test for 
the finding of occult blood in the stooL which i suggesti ve of co lorec-
ta l cancers and large polyp . However, the FOBT is significantly less 
sensiti ve and pec ifi c than co lonoscopy. A lso, the test characteri sti cs of 
FOBT vary igni ficantly depending on the brand, co llection technique. 
and number of samples taken per test. 6 
A lthough imperfect, co lono copy does offer improved sensiti vity 
compared to other test . A nd while the invas iveness. cost. and ri k of 
complication are frustrating drawbacks. they have not ob cured its im-
portance in the creening and diagnos is of co lorectal cancers. Rather. 
they have spurred innovation aimed at modi fy ing tandard colonoscopy 
to address its limitations. 
ADVANCED TECHN IQUES 
I 'irtual Colonoscopy 
A less in va ive alternati ve to traditional colono copy is virtual co lo-
noscopy. also known as CT co lonography. A helical CT image is used 
to create a computer generated 3-dimentional model of the co lon. The 
model can then be visualized digitally for the presence of polyps. 19 CT-
co lonography i non-invas ive, doe not require edation, and avo ids ma-
jor ri sks such a bleeding and perforations.21 However. in the event of 
a polyp being detected a standard co lonoscopy is still required for its 
removal. As with standard co lonoscopy. bowel preparation is required 
and the result depends upon the operator 's skill in the interpretation of 
the results2 1 A poss ible risk of screening with CT- co lonography is that 
the radiation exposure might promote new cancers- a published esti-
mate is a 0. 14% ri sk.19 Though few centres are equipped to carry out 
the procedure, recent guideline have endorsed it as uffic ient screen-
ing once every five years for average risk indi v i d ua l s.'~- 6 Currently. CT-
colonography is mostl y used in the ituation of a technically di fficult 
colonoscopy (excessive co lonic looping) or di verti cula is. and may be 
advantageous to increase compliance in patients who cannot tolerate 
standard colono copy. 2 L 19 
Capsule Endoscopy 
Similar to CT-co lonography, capsule endoscopy aims to avoid the inva-
iveness of traditional colonoscopy. In capsule endo copy, a mall pill 
equipped with a camera is swallowed and pa ed through the bowe l to 
collect imagesY Capsule endo copy does not allow for biopsy or opera-
tor steering, and still requires a dietary bowel preparation. but doe not 
require sedation.23 Though at pre ent it is used in Europe, investi gations 
of the current technology indicate a lack of sensiti vity to warrant replac-
ing other screening testY 
CONCLUSION 
Since its development, colonoscopy ha been widely u ed to screen for 
and diagnose colorectal cancers. However, because it is an in vas ive and 
costly test that requires extensive preparation by the patient and techni-
cal experti se to be performed it is not ideal for thi s purpose. In respon e 
to these limitation . several innovations have focused on less in vas ive 
and more accurate means of screening and di agnos i to compliment 
standard colonoscopy in the management of colorectal cancers. 
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Helping You to Health Yourself 
North Perth Family Health Team is recruiting three Family Practice 
physicians. We are a medical community of 10 physicians providing 
a full range of services including ER/ORJOB/InpatienUOffice practice 
with comprehensive electronic medical records that link Listowel 
Memorial Hospital . W ingham Hospita l and London hospitals. We 
have an underserviced designation and are located 40 minutes 
from Stratford and Kitchener-Waterloo . 
A new hospital wing for our 50 bed faci lity (ER, OR and Diagnostic 
Imaging) was completed in the past 5 years and has attracted a full 
complement of surgical , pediatric and internal medicine consultants 
who regularly visit our site . A new family health facility , the Fisher 
Family Primary Care Centre was built in February 2012 . We enjoy 
the full support of our local community partners and hospital in this 
diverse and dynamic rural practice . 
For more information please visit our websites at www.npfht.ca and 
www.northperthhealthcarerecruitment.ca or contact Kim Kowch 
Health Care Recruiter at kkowch@northperth.ca. ' 
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ETHICS AND LAW 
The final gift: ethical and legal considerations of 
liver donation and patient selection 
Jonathan Fairbairn (Meds 2014) and Niran Arg intaru (Meds 20 14) 
Faculty Reviewer: Dr. Paul Marotta, MD, FRCPC (Department of Gastroenterology) 
The first li ver tran plants were performed in 1963 on three patients. with the longest survi ving for 22 day .1 The ability to ustain patients beyond the 25% one year sur ivai een throughout the 
1970s was made poss ible by the introduction of a key immunosuppre -
sant agent. cyclosporine A in the early 1980s.2 Living donor li ver trans-
plantation (LDLT). which in vo lve a li ver re ect ion of the right li ver 
lobe in adu lts. and the left lobe in children " a first performed in 1988 
in a pediatric recipient and 1996 in an adult recipient.3 At press. L 742 
li ving and deceased donor li ver tran plant have been performed in Lon-
don. Ontario .~ 
Liver transplantation is a life-sav ing procedure with the ability to 
significantly decrease mortality and morbidity for high-need patients. 
Procurement of organs for any type of transplantation i a major limit-
ing factor and presents a significant challenge to their fair and equitable 
distribution. Currently, there are 218 people waiting for a I iver transplant 
in Ontario.5 Patient se lection. therefore. aim to max imize the benefits 
of transplant while minimizing the ri ks as ociated with the procedure. 
There are multiple ethica l considerations applicab le to patient se-
lection and organ donation practices. Legislation governing organ and 
tissue transplantation also play a cen tral role in patient se lection. Here 
we explore some of these ethical and regulatory considerations of li ver 
transplants and the widening gap between demand and supply in Canada. 
RECIPIENT SELECTION 
Organ donation represen ts a ·'final gift .. one can be tow on another in-
dividual. This sentiment impo es sub tantial re ponsibility on the medi-
cal system to se lect suitable rec ipients in an ethical and just manner. In 
addition to numerous immunological and phys iological considerations, 
relevant social factors need to be considered when allocating a finite 
resource for which there i uch high demand. hould patients who re-
quire transplants as a result of their own action . uch a alcohol related 
disease or IV drug use (Hepatiti s B. Hepati ti ). be cons idered on eq ual 
grounds wi th those req uiring a li ver tran plant due to circumstances out 
of their control? 
Eunice Booker, the mother of an organ donor was quoted in The 
Guardian as saying " I find it offensive that one in four livers donated 
goes to alcoholics ... [The li ver should go to] the one who' not an alco-
holic, they are more entitled."6 Further. the rate of alcoholi c rec idi vism 
post-transplantation is estimated at I I to 22%.7 In addition, IV drug use 
{IVDU) use is a significant cause of Hepatiti s . which i the most com-
mon indication for li ver transplantation among adults. Retranspl antation 
for recurrent I-ICY infections is estim ated at 3.6%-5.0%. 8 
Whether a patient is responsible for their past alcoholism or IVD 
use poses the question of whether individual that abu e sub tance are 
exercising free will. If they are deemed not to be free agents. penalizing 
them would be unfair. Many arguments could be raised on both side 
of the issue. including the strong genetic preponderance to alcoholi m. 
and the higher pre alence of comorbid p ychiatri c illnesses among sub-
stance abusers. In addition. the time elapsed between when the caus-
ati ve behavior has ceased and when transpl antati on is necessary may 
be a significant duration. even decade . The legal system ha tended 
to be lieve those abusing substances should be held accountable. How-
ever. given the aims of the legal system are to uphold justi ce and apply 
criminal punishments. while the med ica l system aims to allocate med i-
cal resources and hea l. the role of free wi II in dec ision-making may not 
be the same. Further, thi can lead down a I ippef)' slope: Do alcoholics 
deserve a li ver? Do smokers de erve a lung? Doe a treet-racer deserve 
an ICU tay following a era h? 9 
A s medical innovation re ult in an increa ed number of chronically 
i ll and older patients being eligible for l ive r tran plant. it i important 
to consider the presence of comorbidities and the patient"s age. Thus. 
should an elderl y individual with multiple comorbid ities be con idered 
on equal grounds with a young adult without any comorbidities, who 
has the potential of a con iderably longer lifespan and better outcomes') 
Utilitarian ethic would favor donation to the younger and healthier pa-
tient. However. widespread appli cati on of thi s criterion would system-
atically exclude older and icker patients from transplantation. Given 
the moral obligation of providers to all patients. thi s would lead to an 
unjust outcome. 
The so lution of anadian transplant organizations to these issue is 
a pragmatic one. which generally avoid pa ing moral judgments. and 
circumvents adding qualifiers to the va lue of human life. The Model for 
End-stage Li ver Disease (MELD) is a scoring ystem used to estimate 
di sease severity. This model i w idely implemented in the US, and in-
creasingly in anadaY1 When an organ becomes avai lab le. recipients 
are considered tarting with the patient in greatest need and sequentially 
going down the li st. checking for compatib ility between the donor and 
potential recipient (including body size and blood type). 11 
In Ontario, the relevant human ti ssues leg i lation i the Trillium Gift 
of Life Network (TGLN) Act. The Ontario waiting list is managed by 
TGLN. The transplant organi zations have protocol to communicate 
with one another. and will cross-match medi ca lly urgent patients. When 
an interprovincial donation occurs, tran portation. even acros Canada 
can be arranged in a matter of hours. However, in part due to the frag-
mented transplant network , organ are only occa ionally donated out-
side a province. The system in Canada i in contrast to the U.S., which 
has a national registry. known as the United Network for Organ Sharing 
(U OS)9 
ORGAN DONATION AND SUPPLY 
There are two sources for li ver donations: li v ing donors and cadaveric 
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donors. Out of the 6.000 transplant performed in the United States an-
nually. only 320 are li ving donor transplants. 13 Donation after Cardi ac 
Death (DCD). or .. non-beating heart donor •·• are cadaveri c donors who 
donate fol lowing w ithdrawal of life support . While D Ds were per-
formed many years ago in Canada. they were re-introduced after a na-
ti onal forum in 2005 . 1 ~ The London Hea lth Sc iences Centre (LH SC). a 
anadian leader in the fi eld. is the prov incia l leader. hav ing tran planted 
over 30 of the 100 DCDs performed in Ontari o. 1 ; 
Regarding determination of death. there is no federal leg islati on 
1 hich define death in Canada. ome prov inces, including ntari o, 
have leg islati on that require the determination of death be made by two 
physicians. The United States· Umformed Determination of Death Act 
pec ifies that death may bee tabli shed by irreversible lo of neurolog i-
ca l functi on ('"brain death .. ). or irrever ible ces ation of cardiorespira-
tory functi on.16 The laner criteri a is used in cases of DCDs. 
Criti cs of DCD have noted that ince the patient are ustained on 
life support. their death is not inevi table. Further. DCD as oc iates with-
drawal of end-of-li fe care wi th organ procurement. in a manner nearl y 
ideal for transplantati on. In order to prevent conflicts of interest. and to 
mai nta in publ ic upport of DCD. it i imperati ve to ensure the medica l 
professions who decide to withdraw end of li fe care are not assoc iated 
with organ transplantati on. This supports the "dead donor rul e" that or-
gan donation should neither cause nor hasten death . 
Even with DCDs as a source for organ donat ion. the organ supply i 
unable to meet demand. One trategy proposed to increase the supply i 
switching to an .. opt-our· system. Currently. Canada's "opt-in·· system 
a sumes one does not wish to donate unless they otherwi se speci fy. In an 
opt-out system. uch a Spain 's, one is assumed to want to donate their 
organs unless otherwise specified. In addition. given society's reverence 
for the importance of the human body. even though an indi vidual ' ri ghts 
cease with death. an opt-out pol icy may be seen as a transgre ion of 
the state. Further, public health cam paign to increase awarene s and 
improve cadaveri c donation rates. including the recent Ontari o Gift of 
L i fe Campaign (http ://1\W\\.giftoflife.on.ca/en/ ) have been widely im-
plemented. 
In most provinces. except Mani toba and Quebec. a patient ' recorded 
consent constitutes lega lly-binding consent to organ donation. Nonethe-
less. patien ts are encouraged to make their ub titu te decision maker 
aware of their choice • to ensure wi hes are foll owed. In Ontari o, the 
T LG Act note consent is lega lly binding and prov ides lega l immunity 
to phy ician who act in good fai th wi th regard to organ procurement. 
However, even i f the deceased patient 's con ent i clearly indicated. 
physicians tend to consult fami ly member before proceeding wi th or-
gan procurement. 
Li ving donor li ver transplantion (LDLT) has been effecti vely used in 
Canada for the past forty years. However. ince a I iving donor ha an es-
timated 0.2% mortality risk in adult-to-adult transplant , the proced ure 
is not without ethi cal considerati ons. 17 Potential li ving donors are often 
healthy indi viduals. for which the occurrence of even a low probab ility 
of mortali ty is co tly and should be avoided. Thi may ex pl ain the low 
rate of LDLT in Canada. Even though they are willing and infom1ed 
donors. performing such a ri sky procedure violates the non-maleficence 
principle. Further, these donors often incur signifi cant costs from lost in-
come and trave l expenses. While it is ethi cally unacceptable to purcha e 
an organ. it may be filling to compensate donors for their personal co ts. 
Currently Canada does not have a nati onal trategy to reimburse li ving 
organ donors.1x 
Donor compensati on raises the i sue of organ trafficking, in which 
patients circum vent wa itlists by pay ing for and receiv ing an organ and 
medica l care. When the procedure occur in a foreign nation. it is_ LOm-
mon referred to as transplant touri sm. Often the donor rece ives msuf-
fi cient medical care, plac ing them at ri sk. The Canadian govem~ent 
· · · I 1-1 an Tt ssue condemns organ trafficking. and the vanous provmcta ~m . 
Graft Acts directly outlaw pay ing for human ti sues. The C~tmmal Code 
outlaw any situation where a person is compelled to prov tde organs_ or 
ti ssue . However, how thi s will be applied in relati on to organ traffickmg 
remain to be seen. Further. Canadian phys ician may fee l uncomfort-
able treating patient who have been invo lved with organ tra~ck_ing. 
Nonetheless, as w ith other case in which physicians are consctenttou 
objector . thi cannot prevent a patient's access to care.9 
CONCLUSIONS 
In many way organ transplantation represent the pinnacle of our bio-
medical understanding of human physiology. De pite medica l advances, 
progress is hindered by the lack of upply. which has struggled to keep 
up even with the introducti on of li ving donation and DCDs as we ll as 
mass ive public awareness campaigns. It i therefore the responsibili ty 
of every health care provider to ensure patients are we ll -educated and 
informed of the desperate need of organ donati on. A nd as far as the ques-
ti on of 1 hy to donate. we asked Michae l Bloch. the donor coordinator at 
L HSC and hi view i that: 
'· You have an opportunity of pro iding numerou people w ith im-
provement of their health and in fact ave their l ife. It is human nature to 
help fe llow human being . o i f it i the Ia t good thing you do in your 
li fe. or even the onl) good thing you do in your li fe. I can' t see why you 
will not" . 19 
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It 's more than a practice ... 
it 's a lifestyle! 
We warmly welcome students and new 
graduates to Family Medicine and a variety 
of specialty areas. 
Northern British Columbia is a region graced with a diverse natural beauty 
found nowhere else on earth . At Northern Health , we are proud to be a state-
of-the-art, integrated health care provider, caring for a population of over 
300,000 across Northern British Columbia . 
Come talk to us! 
We invite you to consider a personal and professional adventure and to 
discover the benefits of a front-line healthcare practice in an extraordinary 
setting. We offer a progressive and consultative work culture as well as leading 
relocation assistance. 
Start your life and your practice in Northern BCI 
I Please call 1.877.905 .1155 or visit our website to find out all that our region and orgamzat10n has to offer and how to make the most exc1tmg move of your life. 
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HEALTH POLICY AND ECONOMICS 
Biologic agents in the management of 
inflammatory bowel disease: is it worth it? 
Tommy Choy (Meds 2015), Jessica Jackson (Meds 2015) 
Faculty Reviwer: Dr. John Howard, MD, FRCPC (Department of Medicine and Paediatrics) 
I NTRODUCTION 
Infl ammatory Bowel Disease ( lBO) represents a group of disorders that 
affects the gastrointestinal (G I) tract. In thi disease. an abnormal im-
mune response in the body cau e inflammation and ulceration of the 
Gl tract. The two main form of lBO include rohn "s di ease ( 0 ) and 
ulcerati ve colitis (UC). which differ in their presentation and treatment. 1 
Crohn " disease can affect any part of the G l tract. and the entire thick-
ne s of the inte tina) \\ all is generall) in vo lved. Ulcerati ve co lit i • on 
the other hand. is limited to the rectum and colon and the exteri or layers 
of the intestinal wa ll are generally not affected. lBO is a lifelong dis-
ease that has a sub tanti al impact on the quali ty of life of patients and 
has a tremendou impact on a patient' we llbeing. There are currently 
no cures available for lBO and treatment is aimed toward keeping the 
patient symptom-free. 1 
I BD i most commonly found in the developed world. although ca es 
have begun appearing more frequently in developing countries 2 Glob-
ally, Canada and Sweden have the highe t incidence of both CD and 
UC.2 It is e timated that more than 5000 case of CD and 4000 cases of 
Care diagnosed in an ada each year, with a total of more than 200.000 
Canadians li ving wi th one of the e di ea es at any given time. 
The heavy burden that lBO impose on patients in tum leads to 
ubstantial fi nancial costs for the Canadian healthcare ystem. Due to 
the nature of lBO. the e costs include both direct costs a oc iated wi th 
treating the disease and indirect cost such a lost producti vity and time 
mi ssed from work. In a 2008 report by the rohn "s and Colitis Founda-
ti on of an ada. it wa found that the indirect cost as oc iatcd with I BD i 
approx imately $1 bill ion dollar annually, wi th CD compri ing roughly 
$600 million of that va lue due to its higher preva lencc. 1 Direct medica l 
costs for lBO in Canada are estimated at over 750 million, with CD ac-
counting for two-thirds of that va lue. 3 A lthough the e co t \\ i ll continue 
to increase a the preva lence of lBO grow . the distribution of the direct 
medical co ts have recently undergone ignifi cant changes due to the 
introduction of new treatment options. The remainder ofthi arti cle will 
address these speci fic change . 
T REATMENT - PRE BIOLOG IC ERA 
Prior to the introduction of biolog ics. the maj or categori c of medication 
prescribed for the treatment of lBO included aminosalicy latcs. cortico-
steroid and immunomodul ato rs. ~ In the event of failed medical therapy, 
urgery wa also con idered. Resections were idea lly conservati ve and 
only undertaken for symptomati c patients. \ 
In both CD and UC. roughly one-third of total co ts are concentrated 
in the mo t evere patients (2% of all patient ). who are often re istant 
to traditional drug therapy.'' Medication cost arc relati ve ly inexpen ive 
when compared to the urgica l interventions and re lated hospitali zati ons 
required by these patient . In fact. surgical interventions account for 
the greatest porti on of the cost of I BD.6 Parenteral nutrition is another 
co tl y intervention. which was reported to be re ponsible for majority of 
overall pharmacy co ts. despite in frequent use.6 Pharmaceutical used 
to repre ent le s than I 0% of overall health care cost related to the treat-
ment of I BD, but thi s va lue has increased in the post-biologic era3 
T REATMENT- POST BIOLOG IC ERA 
The fi rst biologic agent was appro ed in 1998 and has ince become a 
popular lBO treatment choice. In most in tances biolog ic agents are 
initiated for patients who demonstrate an inadequate response to con-
ventional therapies. There are currently four agents approved by the US 
Food and Drug Administrat ion for treating CD and one agent available 
for use in UC. lnfli x imab is a murine chimeri c monoclonal antibody 
directed aga inst tumor necrosis fac tor (TNF) -alpha. and can be used in 
both acute attacks and maintenance therapie .7 It is also the only agent 
ava ilable thu far in treating UC.8 Ada limumab and Certolizumab pegol 
are humanized anti-TNF agent and are approved for use in treating pa-
ti ents who have lost re ponse to lnfl ix imab.7 Lastl y. Natalizumab is a 
humanized ant i-alpha-4 integrin ant ibod) and i u ed in patients who 
cannot tolerate anti-T F agent .7 
In Canada. the cost for biolog ic agents wa estimated to be over $1 10 
million in 2008. compri ing over two-third of overall drug co t. 3 Thi 
va lue ha ince increa ed with more agent appearing in the market. 
World-wide. it is estimated that anti-TNF ale will peak at over 2 bil-
l ion in the coming year . and the overall market for I BD wi II reach 4 bi I-
lion U dollars in 20 1P In addi ti on to thi gro,,ing selecti on of avail-
ab le agent . there has also been a change in the pre cripti on habit of 
physicians that has contributed to thi s increase in cost. The average time 
from diagno i to biologic treatment initiati on ha decreased from 7-8 
year to 3-5 year . and it i likely that thi s trend of early treatment' ill 
continue.' In light ofthi trend. many studies have been done to study the 
cost effecti venes of aid agents. 
COST EFFECTIVENESS O F BIOLOG IC AGENTS 
Overall . most studi es done to inve ti gate the cost effecti veness of bio-
logic treatment of lBO have demonstrated a decrea e in neces ary hospi-
tali zati on and urgica l intervention . One study done at the Uni versity 
of hicago demonstrated a decrease in all surgeries by clo e to 40%. 
emergency room visits by over 60% and decrease in ho pitali zation by 
over 50%. 6 Another tudy in pain reported that the cost of hospitali za-
ti on was reduced from 60 percent down to 6% of total annual health ex-
penditures for the treatment of IBD. 111 Despite the e positi ve outcome 
these studie also indicated that the overall cost of l BO managemen; 
actually increased a a re ult of bio logics usage. That being aid, a more 
costl y intervention can still be cost effecti ve a long a there is a uf-
fi cient increase in health outcome. For example. the National Jn titute 
28 UWOMJ 1 81 :2 1 Fall 2012 
for Health and Clinica l Exce llence (N ICE) sugge ts that an incremental 
cost-utili ty rati o of20 ,000 to 30.000 pounds (roughly $32000 to $48000 
A dollar ) per quality adjusted li fe year (QALY) ga ined can be con-
sidered cost effecti ve. 11 
Early studie reported induction therapies of infl ixi mab for acute at-
tacks to be greatl y cost effecti ve according to the above NICE guideline, 
however, these were all short-term one year studie .12 Thi short time 
frame likely led to an overestimate of the co t-effectivenes rati o due to 
the chronic nature of IBD. Indeed, subsequent studies \ here the tudy 
time hori zon was expanded to 5 years revealed that the use of biologic 
agents in acute attack approached cost effecti veness. Lind ay et a/. re-
ported that lnfliximab was co t effecti ve for both luminal and fi stuli ing 
forms of CD, however. body weight was an important facto r affecting 
cost effecti vene .13 An ev idence review group in the Uni ted Kingdom 
reviewed the u e of infliximab in exacerbations of C and fo und an 
incremental cost-utility ratio of roughly $32,000 US do llars. with the 
results being ensiti ve to the pati ents' colectomy rate .14 A systemati c 
review on the use of infliximab in CD was done by the National In titute 
fo r Health Research and it reported that infliximab was cost-effecti ve fo r 
epi odic treatment of acti ve CD.11 
Contrary to the evidence fo und in inducti on therapies, studies have 
reported poor results for the u e of biologics in lifelong maintenance 
therapies. French authors reported that the incremental cost per QA LY 
fo r infliximab in li fe time maintenance therapy ofC D was more than 10 
times that of the rati o for induction therapy. 15 imilarly, Bodger et a/. 
fo und continuous therapy of infli ximab to only be economica lly fea ible 
fo r up to 4 years. 16 Evidence for models with a horter time hori zon 
has also been mixed. '"The Crohn 's Trial of the Fully Human Antibody 
Adalimumab for Rem ission Maintenance tri al"· data reported that for a 5 
year hori zon. maintenance of adalimumab will result in an incremental 
ratio of less than $48,000 per QA LY in CD.17 'T he Active Co litis Treat-
ment tri als" also reported similar fi ndings fo r the use of infliximab in 
UC patient .18 On the other hand. Kaplan et a/. from the United tate 
have found an incremental ratio of $33 2,000 per QA LY for infliximab 
use in CD19, and a y tematic review done by the Canadian Agency for 
Drugs and Technologies in Health reported an incremental rati o of over 
$200.000 fo r both infliximab and adalimumab in CD and $350.000 for 
using inflixi mab in UC.20 
Part of the rea on fo r the heterogeneity of result can be attributed 
to difference in the cost of administering the agent between countries. 
Although the cost for I OOmg of infliximab is fa irly stable at a price range 
of ($700-900 US dollars), patient in the United States, but not the UK 
must pay a substantial fee fo r the ervices of an in fusion center. 6 Greater 
cost containments in both drug and administrati on co t will li ke ly be 
needed to ensure cost effecti ve care. Another signifi cant caveat of these 
tudies is the fact that indirect costs were not accounted for in their cost 
effecti veness model . This is likely to cause a gross overe timation of 
the cost effecti vene s ratios for biologic agents.6 La tly, it should be 
noted that meta analyses were not perfo rmed as a result of signifi cant 
heterogenei ty between studie , o a definiti ve answer on the matter is 
unavailable.11 ·211 
CONCLUSION 
Biologic agents have been shown to provide clinica l benefit in pati ents 
with moderate to severe attacks of CD and UC. In turn, the increas-
ing use of the e agents in treatment of IBD has rai ed concern about 
whether or not these drugs are a cost-effecti ve u e of health care re-
sources. Current ev idence suggest that biologic agents are likely to be 
cost effecti ve when used to treat moderate to severe acute attacks of CD 
and UC. Ev idence for its use in maintenance therapy is inconclusive and 
more re earch in this area is recommended. 
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Is it what you know or how you use it? A review 
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I t i no secret that a number of chroni c di ea es. including cardio-vascular disea e. cancer. diabete mellitus. and obesity. are causing increasingly more di ability and premature death around the world. 
and that poor nutrition is a modifi ab le ri sk factor for these diseases. 1 
Given the prominent role of nutrition in the global burden of disease. 
it i essential that today· medical tudents receive an adequate amount 
of nutrition education. It is al o important that practicing physicians are 
providing their patients wi th evidence-based nutritional coun eling. 
Based on a series of surveys conducted between 1999 and 2009. 
62%-73% of medical schools in the Uni ted States were not meeting the 
minimum target of 25 hours of nutrition education aero the four years 
of undergraduate medical educat ion. as recommended by the ational 
Academy of Science .2 Canadian medical schools do not seem to be far-
ing much better. at least according to students. A questionnaire given to 9 
of the 17 Canadian medical chools revealed that 87.2% of med ica l stu-
dents who re ponded felt that thei r program needed to devote more time 
to nutrition instruction 3 There may be a number of barriers to achiev ing 
the optimal amount of nutrition education. including limited time in the 
curriculum. lack of nutrition pecialists on facu lty. and greater weight 
being given to the treatment of disease rather than its prevention . 2 ·3 -~ 
The questionnaire given to Canadian medical tudent indicated 
that some components of nutrition curricula may be stronger than oth-
ers. The majori ty of respondents were comfortable with ba ic nutrition 
concepts and the role of nutrition in hea lth promoti on.3 However. most 
lacked confidence in their knowledge of nutritional requirement at di f-
ferent points in the lifecyc le and thei r ability to discuss the role of nutri-
tion in the treatment ofd isea e.3 It is important that med ical tudent are 
exposed to nutrition education that provides them wi th practica l skill s. 
such as nutritional assessmen t and counse ling. in addition to the ba ic 
science component. 2 
Regardl ess of the quality of nutrition education received. it i likely 
that medical student wi ll vary in their atti tude towards nutritional coun-
se ling. Several studies have found that female medica l student are more 
likely to ask their patients about diet or engage in nutritional counsel-
ing than their male counterparts. 5·6.7 It has also been found that med i-
cal students intending to specialize in primary care were ignifi cantly 
more likely to consider nutritional counseling important than students 
intending to pursue a career in a subspecialty. 7 lntere tingly, the same 
study determined that medical students who con umed more fruits and 
vegetab les themselves were more likely to deem nutritional counse ling 
relevant to their clinical practice.7 Educational methods for increas ing 
students' provision of nutritional advice might therefore include demon-
strating the relevance of nutrition in subspecialty practice and encourag-
ing students to improve their own diet and knowledge of healthy cook-
ing. 
Some program s have found ways to overcome the many barriers that 
stand in the way of achiev ing adequate nutrition ed ucation in medica l 
chools. The Uni versity of Arizona College of Medicine managed to 
increase the time devoted to nutrition instruction in their program from 
35 hours to 75 hours by implementing an integrated nutrition curriculum 
that incorporated nutritional topics into a variety of courses. including 
biochemi try. ocial and behavioural sc iences. and preparation for clini-
cal medicine .~ This approach also improved the tudents· clinica l ap-
plication of nutritional knowledge and sk ill s. utrition scores on the 
Objecti ve tructured Clinical Examination (OSCE) were ignificantly 
higher (P < 0.05) for students who had been expo ed to the new curricu-
lum. compared to those who had graduated before it was implemented . ~ 
While an integrated curricu lum repre ents one approach to contend 
with a l imited number of lecture hours. another way to overcome thi s 
barrier might be to have tudents complete some of their nutrition educa-
tion online. Researchers at the Uni versity of North Carolina at Chapel 
Hill have developed an online nutrition curricu lum ca lled the utnt1on 
in Medicine (N IM ) project. which was being used by 90 of the 156 
A meri can medica l schools when their paper was published in 20 I 02 
The online modules are designed so that users wi ll develop practical 
sk ills such a as es ing a patient's nutritional status or prescrib ing nu-
tritional interventions a treatment. 2 Thi kind of online program wou ld 
likely help to address ex isting defic its in nutritional education. like the 
cl inica l application of nutritional knowledge, while compensating for 
time constraints and standard izing nutrition instruction across different 
medica l school . 
When one con iders the current state of knowledge among prim ary 
care phy ician , an interesting pattern emerge . Over 80% of Canadian 
family phys ician rated their medical schoo l nutrition traini ng as in-
adequate. M any doctors stated that they wanted more direct training 
on nutrition during thei r undergraduate and postgraduate education.8·9 
However. survey asking phy icians about their current state of knowl-
edge demonstrate that over 60% believe they know ·very much· about 
prescribing diets for weight-loss10 and over 75% believe their nutritional 
knowledge is ""up-to-date". 11 In one focus group. mo t doctors agreed 
that their level of nutritional knowledge was adequate to deal w ith most 
common hea lth problems.12 Indeed, when given objective tests of nutri -
ti on knowledge. most family phys icians answer the majority of ques-
tions correctly. albeit with certain gap . 11 When asked about the sources 
of their nutritional information, most phys ician cite sel f-directed learn-
ing and reading,R·12 while some cite Continuing Medical Education 
(CME) courses. 13 
Mo t studies agree that primary care physician seem to have an ad-
equate level of knowledge about nutrition . Nonethele s. only 40% of 
obese patients are counse led to lose weight by their phys ician 10 and there 
is a significant difference between the number of patients that wou ld ben-
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efit f rom dietary advice and the number of patients that actual ly rece ive 
counse l ing. 8 When asked about barri ers to providing dietary advice, the 
answers were mixed. A Canadian study cited lack of time and lack of 
compensation as the largest barriers,8 and lack of time was echoed in a 
UK study as well. 1 ~ A Scandinav ian study reported lack of nutritional 
knowledge as the primary barrierY and an Israe li study mentioned patient 
apathy and non-compliance as a barri er to providing nutritional adv ice.1; 
Patient and phys ician beliefs can also be barriers to effective nutri-
tional counse l ing. While the large majority of primary care physicians 
believe that counse ling is part of their role. 15-16 many doctors believe 
that nutritional counseling usual ly doe not help their pati ents 13 • 1 ~ andre-
port feeling frustrated and pe simisti c about the effectiveness of dietary 
advice. 10 Interestingly. phys icians that reported more nutritional knowl-
edge were more likely to discuss nutrition wi th their patients, and more 
likely to believe that it was effecti ve. 8· 1" Patient report lack of nutritional 
knowledge as the primary barri er to making dietary change; phys icians, 
however. overwhelmingly be lieve patient apathy is the biggest barri e r. 1 ~ 
Both patients and phys icians often believe nutritiona l counse ling is not 
necessary without an acti ve medical diagnos is. with patients much less 
li kely to view obesity as a medica l diagnosis. 1;· 16 
Moore e / a/. 1 ~ prov ide a compelling explanation for the gap between 
hav ing adequate nutritional knowledge and providing effecti ve nu-
triti onal counse ling. They bel ieve that the problem lies in knowledge 
translati on - the ability to apply knowledge in a way that lead to be-
havioural change. Physicians are primaril y trained in the management 
of disease. and not in health promotion or preventati ve medicine. Phys i-
cians that consciously include moti vationa l statements in their dietary 
adv ice, or who were trained on moti vati onal counseling techniques. 
were more succes fu l in achiev ing dietary change from their patients. 8 · 1 ~ 
Pignone el a /. 11 defines counseling as .. a cooperative mode of interac-
tion to ass ist patients in adopting behaviours associated with improved 
hea lth outcomes". There are many sty les o f cou nse ling used by phy-
sicians. A n informational sty le include providing patient with nutri-
tional facts and written materi als. A reference sty le includes referring 
patients to a dietician for specific nutritional advice. A moti vational sty le 
includes a hoi istic assessment of the patient 's readiness for change, and 
is w idely con idered the most effecti ve method . 1 2 · 1 ~ Many phys icians are 
already attempting to provide strong nutritional counseling to their pa-
ti ents, and 80% be lieve that they are ··occasionally"' success ful in help-
ing patients make dietary change. 1" 
A recent systematic rev iew de cribe nutritional counse ling tech-
niques and interventions that are most successful at improvi ng pati ent 
hea lth.17 This rev iew included 2 1 RCTs wi th objecti ve endpoints - bio-
chemical marker (i .e. serum tri glycerides) or anthropomorphi c mea-
surements (i.e. wai t circumference). The most effecti ve interventions 
had a number of shared characteri stics. They included an initial dietary 
assessment, family in vo lvement wi th social supports. group counse ling. 
and goal-setting. They also di cus ed not on ly food intake. but also food 
preparati on techniques. While these are admirable goals, it is not always 
feas ible in a primary care setting. Eaton el a/. 1' found that phy ician 
spend an average of I minute di scuss ing nutriti on in a routine primary 
care appointment. However, Pignone et a/.11 also discu ssed ' medium-
inten ity' interventions that were moderately effective and would be fea-
sible in primary care. The e included a combination of targeted elf-help 
materials, given directly by the hea lth care provider, fo llowed by brief, 
face-to-face provider adv ice . M oore el a /. 1" support thi s finding, stat-
ing that the goal of prim ary care phys ician hould be to reinforce and 
legitimize the ava ilable public health advice on nutrition. 
How can we des ign educational program that will help medical stu-
dents and curren t phys icians deve lop into strong nutritional counse lors? 
The introduction of innovative nutrition modules shou ld focus on two 
main areas: the application of nutritional knowledge in the prevention of 
disease and manaoement of common chronic conditions, as well as tech-
niques for couns:ling and motivating patients to change their dietary 
habits. New intervention s, des igned for both medical chool and pn-
mary care practice, seem promising in thei r abi l ity to meet these goals. 
utrition is a vital too l in primary preven tion and health promotton, and 
hopefully wil l be increasingly recognized a such in the medical com-
muni ty. 
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INTROD CTION 
Irritab le bowel syndrome ( IB ) i a gastro intestinal di sorder charac-
teri zed by chron ic abdominal pai n and irregular bO\\ el function in the 
ab ence of an organic cau e. It i e timated to affect ten to fifteen per-
cent of the orth merican populati on. w ith higher preva lence among 
younger and femal e patient .1 While only a minority of patients seek 
medical treatment. I BS con titute more than a quarter of gastroentero l-
ogy referral each year.1 
A IBS is a chronic condit ion with no known cure. treatment plans 
have focused on rei ief of abdomina I ymptom and address ing any other 
patient concerns. 1 This ha grown to include alternati ve therapies, in-
cluding acupuncture. In 2003, the World Hea lth Organization listed ir-
ritable co lon yndrome a a yndrome for which ··acupuncture is worth 
try ing because treatment by conventional and other therapies is di ffi -
cul t" '. though they stre that there are only individual controlled trials 
reporting orne therapeutic effect .2 A t present time, the evidence for 
effecti veness of acupuncture fo r treatment of I B remains inconclusive. 
Acupuncture theory, recent research fi ndings and implications of acu-
puncture use in IBS treatment will be discu sed be low. 
Acupuncture i an ancient form of Chine e medici ne "' hich in-
volves inserting solid. ·atraumatic· and stainle tee l need les into the 
kin at peci fic poi nts on the body. These point . known a acupoint . 
have been theorized to have a lower re istance to passage of electri c-
ity than the urrounding kin. and are con nected by the fl ow of Qi. or 
energy. th roughout the body. 3 A n) imbalance. ob !ruction or m i direc-
tion of this mo ement ofQi i thought to lead to di ease. or potential!) 
increase susceptibi l ity to i llne .1 upporters of the practice believe that 
acupuncture is used to correct the Qi imbalance, re loring a balance in 
autonomic nervous sy tern function. treating ymptom and prevent ing 
illness.3 pecifica lly fo r IBS. acupuncture i thought to re tore ba lance 
to the autonom ic nervous sy tern , which i in dy rhythrnia due to dis-
parity in Qi of the pleen, kidney and/or li ver.3 Research has uggested 
that treatments of traditional and electroacupuncture can influence the 
physiology of the gastrointestinal tract, including altering the motility, 
pain thre hold, hormone leve ls and ac id ecreti on of the ga trointestinal 
sy tern 4 ·7 A lthough there has been no conclusive ev idence regarding its 
effect in IB . many acupuncturi sts now cite I B a a potential indica-
ti on for their treatments. 
LITERATURE REVI EW 
urrent ev idence how conflicting result over the benefit of acupunc-
ture. L im el at (2006) rev iewed ix randomi zed control trial of poor 
quality and heterogeneou intervention. and found the benefi t of acu-
puncture use in IB to be inconclu ive.K They noted that in studies com-
paring acupuncture with sham acupuncture. treatment did not otTer 
improvement in overall '' ell -be ing. or in individual ymptoms such as 
diarrhea con tipation. or abdominal pain. Howe er, in a study using 
Chinese herbal medicine a the control. the effect of acupuncture was 
found to be tati ti cally igni ficant.R In a German study by Schneider 
e1 a/ (2007). effect of acupuncture \\ a as essed ba ed on autonomic 
nervou ystem re pon e. pain. and quality of li fe.9 ham acupuncture 
erved as the contro l. Autonomic nervous ystem response to acupunc-
ture was measured by sal ivary cort i ol levels and changes in heart rate 
during a tilt table te t. It was found that for both groups of patients, 
there was an improvement in health related quali ty of li fe as indicated 
by patient respon es to questionnaire . However. for the group treated 
"ith acupuncture. pa in contro l was tatistically improved after I 0 treat-
ments. It" a al o found that patient treated with acupuncture had lower 
sali vary corti ol level , and reduced heart rate increase during the tilt 
table test. indicating increa ed parasympatheti c tone. 
On the other hand. several studies with double blind. ham controlled 
tr ia l have yet to convincing!) prove the benefi t of acupuncture for treat-
ing I B .10 11 In a recent tudy by Lembo el a/ (2009), while it was found 
that interaction with the health care profe sional performing either the 
ham or real acupuncture offered improvement in I B ymptoms ' hen 
compared to no intervent ion. there \\ ere no difrerence in improvement 
between the two acupuncture interventions. 11 
The majorit) of tudies inve tigating the benefit of acupuncture in 
IBS were under po" ered. wi th the large t randomized control tri al in-
cluding only 230 patien t .11 tud) methodolog ie and acupuncture tech-
nique \\ ere heterogeneou . pecifi cally in the number and duration of 
treatments.x 12 These ' ariation made it difficult for rev iewer to pool 
together mailer tudie to elucidate the treatment effect.R 
Dl ION 
cupuncture is becoming increasing!) recognized in anada a an ad-
j unct therap) and hea lth care practitioner are beginning to incorporate 
acupuncture into their kill s of pra ti ce. In most Canadian prov inces, 
hea lth care practiti oners require ex tra training beyond their bas ic pro-
fe ional training to perform acupuncture. The standard for training i 
et by the regulatory bodies for each profe ion. but in many prov inces 
there are till no standard s. 3 urrently in Ontari o. the practice of acu-
puncture is regulated by the Traditional Chinese Medicine A ct. 2006.13 
The Ontari o government is also in the proces of establi shing a college 
whose mandate will be to oversee the implementation of pol icies and 
regulations relating to the acupuncturi t profession. 
A ny di cus ion about the use of acupuncture in clinical practice 
hould always take into account the patient per pecti ve. Current drug 
therapy for IB prov ides linle benefit to patients. thus it i not surpri ing 
that almost 50% of I B patients turn to complementary and alternati ve 
medicine therapie . 1 ~ Furthermore. de pile the lack of e idence to pro-
vide a convinci ng argument for an actual therapeutic benefi t of acupunc-
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ture compared to ham acupuncture, there is at lea t orn e perceived 
benefit due to a placebo effect. In fact. all tri als indicated a signi ficant 
increase in quali ty of li fe independent of the k ind of acupuncture (real or 
ham). 15 It i important to note that the study quality was poor in many 
of these trials. Further investigation is necessary to delineate the effi cacy 
of acupuncture in the treatment of IBS. Finally, there is no ev idence to 
indicate any potential harm for the use of acupuncture in the treatment of 
IB . Given the e circumstances, phy icians should consult their patient 
about the options they are considering and not be openly dismiss ive of 
acupuncture as an adj unct therapy. 
On a final note, while many studies focu on the effect of traditional 
acupuncture compared to placebo ( i.e., sham acupuncture). considerably 
fewer tudies compare acupuncture w ith tandard drug therapy. Certain-
ly. while the u e of tri cyclic antidepressants in the treatment of IB is 
supported by strong clinical ev idence.14 16 there is little ev idence to up-
port the use of antispa modics or se lecti ve serotonin reuptake inhibitor 
antidepres ant .14• 17• 1" We believe that current drug therapies deserve the 
arn e level of scrutiny as acupuncture. Lundeberg et a/ (20 II ) suggest 
that the therapeutic effects of acupuncture can be compared to tho e of 
standard treatment. taking into consideration indiv idual responses and 
circumstance . before deciding on the use or disu e of acupuncture in 
the treatment of I B .1Y 
IBS remains a di fficult syndrome to treat, w ith the main focus of 
management on rel ief of symptoms. A lthough the research remains in-
conclusive. acupuncture may play a role in allev iating some gastrointes-
tinal symptoms and increas ing the qual ity of life for some IBS patient . 
It is up to us as future physicians to work with our patient to determine 
the best management plan combining allopathic and naturopathic medi-
cine. 
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The use of gene expression profiling in the 
personalization of colorectal cancer treatment 
Laura Callan , MASc (Meds 2015) and Melissa J. MacPherson , PhD (Meds 2014) 
Faculty Reviewer: Dr. Brian Dingle, MSc, MD, FRCPC, Division of Medical Oncology 
Colorectal cancer (CRC) is the third most common cancer in Canada. 1 Thi year in Ontario. it is estimated that 8700 people \viii be diagnosed with CRC and 3450 people will die 
of the di sease. 2 Due to the high mortali ty rate of R . screening pro-
gramme have been des igned to screen the population for CRC prior to 
the on et of symptoms. The high burden of disease CRC cau e has also 
made the fie ld of R screening. diagno is and treatment a prime area 
for the development of novel medica l technology. Histori ca lly, th ese 
technologies have been limited to the fi eld of biochemica l testing of 
stoo l and fi ber optic vi uali zati on of the co lon using the co lonoscope. 
A new and exc iting fie ld for technology development is the application 
of molecular genet ic in the profi I ing of co lorectal tumours. Genetic 
profi ling \ ill allow clinicians to deve lop a personali zed treatment plan 
for the administrati on of chemotherapeutic agents and biologics in the 
treatment of CRC. Personali zed medicine ha the potential to improve 
outcome by electing the chemotherapeutic agent that ha the be t I ike-
lihood of effectiveness fo r a given patient" spec i fic tumour. In order for 
thi s practi ce to become the standard of care, links between geneti c pro-
file and chemotherapeutic effecti veness must be kno,vn and technolo-
gies for analys ing the relevant gene profi les mu t be developed. The 
appli cati on of thi s technology to stage II CRC in parti cular is an acti ve 
fie ld of research. 
Currently, the five year survival rate for stage I CR i approx imate-
ly 93%. Thi survival rate fa lls to approx imately 80% for patients with 
stage I I diseaseJ The effecti veness of adj uvant chemotherapy for tage 
II CRC disea e is currently an area of debate in the fie ld of onco logy! 
M oertel et al. conducted a retrospective study looking at pati ents w ith 
stage II RC to identi fy clinica l characteri ti cs that are predicti ve of re-
currence of di ease in order to identi fy patients who might benefit from 
adjuvant chemotherapeutic treatment. These characteristic include 
T4 lesions. bowel obstructi on and tumour perforation. 1 Patients w ith 
high ri sk stage II di ea e. identifi ed using these characteri tic . are often 
treated with adjuvant chemotherapy, desp ite the lack of va lidation with a 
randomized clinica l trial! A n analysis of the merican EER-M edicare 
database--one of the largest medica l databases in the nited States--has 
demonstrated that patient with tage II RC who rece ived adjuvant 
fluorourac il based chemotherapy did not have improved outcomes with 
either high ri sk or low ri k disease.6 onverse ly, the QUA A R study 
has shown that the standard chemotherapy regimen of fluorourac il plus 
leucovorin produces a 3% urviva l benefit in stage II R : however, th t: 
tox icity of the treatment cau es death in 0.5% of patient 7 To make mat-
ters more com pi icated, the addition of oxaliplatin to a chemotherapeutic 
regimen of fluorourac il and leucovorin improves the outcome in stage 
Il l CRC but does not improve the 6 year survival outcomes of stage II 
RCY This surprising nnding highl ights the need for improv ing the 
clinical criteri a for se lecting tage II R patients who w ill benefit from 
adju vant chemotherapeutic treatment. The fi ndings in thi paper also 
sugge t that CRC is not necessarily a stepwise progression from stage II 
to tage 111 d isea e and demon trate the need for further research mto 
the molecular biology of stage II di ease. 
Despite the criteri a for high ri sk stage II CRC outlin~d above and the 
Jim itati on of these criteri a. the morbidity assoc iated w1th treatment for 
stage 11 RC could be greatly reduced i f physician were able to further 
delineate which patient could benefit from adj uvant treatment. The 
molecul ar geneti c profi ling of a patient's co lorectal tumour could po-
tentially y ield thi s in formation by analys ing for the expressiOn of gene 
\\ hich are known to respond better to adj uvant chemotherapy. While 
thi approach is ery exc iting and hold great promise. phy icians and 
researchers need to make sen e of the extensive data that can be gen-
erated using a genomics approach. Knowing the expres ion level of 
all the genes in the CRC tumour i not a practi cal approach to dec id-
ing t rea~ment options for the el i ease. vera l research group have ad-
dressed thi s challenge b) electing groups of genes to profile in an effort 
to determine which genes in stage II CRC are cl inically ignifi cant for 
recurrence. 
n interesting product that i beginning to become available in the 
clinic i the Oncotype Dx Colon Cancer 12 gene assay. This assa mea-
sure the express ion levels of even cancer related genes ( tromal Group: 
BGN. F P. I 1-IBA: Ce ll Cycle Group: MYC. MK 167, MYBL2: Early 
Response Group: G DD458) and normalizes the e genes to a group of 
reference genes that have ver) l ittl e variabilit) in expression (ATP5 E. 
GPX I. PGKI. VD 2. BB).~ The even cancer related gene were 
se lected based on the results of a erie of deve lopment studi es which 
included four independent cohort for a total o f over 1800 patients. 
tarting with a panel o f 76 1 gene- known to be assoc iated with CRC. 
the c en gene mo t as oc iated w ith recurrence ri sk and di fferential 
benefi t w ith adj uvant chemotherapy in tage II RC were se lected to be 
used on the Oncotype Dx 12 gene assay. 7 Ti sue samples for use in this 
parti cular as ay arc fi xed in formalin, a significant technical advance-
ment over other a say ince it means that pathology samples and gene 
ex pre ion pro fi I ing can be obtained from one tumour sample. It al o 
allow gene expre ion profiling to be conducted on prev iou biopsies 
or tumour resecti ons. Briefl y, R A i extracted from the formalin fixed 
tumour and quantified to determine the amount of RNA pre ent in the 
sample. The R A is then reverse transcribed to complementary DNA 
using a gene pec ific primer for each assay gene. The express ion levels 
of the 12 gene are then mea ured using quantitati ve polymerase chain 
reacti ons (PCR) ( ee Figure I for a schemati c of the assay). After the 
molecular biologic analysis is completed, a recurrence score between 
0 and I 00 is then a signed ba eel on an algorithm outlined by Clark-
Langone et al.. 8 A 10\ score (S30) corresponds to a 3 year recurrence 
ri k of 8%. an intermediate score (3 1-40) has a 3 year recurrence ri sk 
of II % and a high core (::::41) ha a 3 year recurrence ri sk of 25%. 1 
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This algorithm take the combined ex pre ion va lues from each of the 
gene group (Stromal, Cell Cycle and Early Re pon e), allowing for co-
expre sion, and combine these values w ith vary ing weight to create 
an overall recurrence core, an indiv idualized ri sk estimate for co lon 
cancer recurrence. While initial results based on a retrospective analys i 
using the QUASAR trial do show an association between the recurrence 
ri sk score and prognosis, the predicti ve va lue of the recurrence score for 
treatment benefi t ha not yet been hown. Further trials are underway 
to determine the ful l clinical effecti vene of the Oncotype Ox Co lon 
Cancer As ayY 
Other similar products on the market include the Co loprint 18 gene 
as ay; 1" however. thi a say is of l imited utility since it only make use 
of fresh frozen tumour samples. The Oncotype Ox Colon Cancer Assay 
uses formalin fi xed ti ssues allowing for the fl ex ibility to al o perform 
HEALTH AND TECHNOLOGY 
patholog ica l analysis of the same tumour sample. While the e emerging 
technologies are not likely to replace the role of pathological evaluation 
of tumours in the diagnos is and stag ing of colorectal cancers wi thin our 
li fetime. they may have the abili ty to complement current practices by 
providing more detai led inform ation on which treatment options are best 
for a particular patient. Despite their promise, several questions need to 
be addre sed regarding their utility. Since a patient has many CRC tu-
mours and not all tumours have an identica l genotype. wi ll the as ays be 
valid at selecting those patients who w ill benefit from adjuvant chemo-
therapy? Moreover, since the genotype of a CRC tumour changes dur-
ing the course of treatment due to the development of drug resistance, 
will the a say be a worth whi le clinica l too l in the treatment of the ever 
evolving stage II CRC tumour? A I o, how much of a urviva l advantage 
wil l adjuvant therapy provide and wil l the a ay be cost-effecti ve when 
analyzed using QALY? Despite the e questions, the u e of molecular 
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Figure 1: A schematic diagram illustrating the Oncotype Ox Colon Cancer Assay. A co lorectaltumour is fi xed in formalin. sent for pathologicar analy-
sis and used concurrently in the Oncotype Ox assay. RNA i extracted from the tumour and is quantified using fluorescent dyes. A known amount of 
RNA is added to a reverse transcription reaction . The RNA is re verse transcribed to complementary D A (cO A) using primers specifi c for each of 
the 12 genes of interest. Quantitative polymerase chain reaction (qPCR) is performed using the eDNA and fluore cent probes. The probes are specific 
for each gene of interest and have a fluore cent molecule ( tar) bonded to one end and a quencher (spira l) that stops the fluorescence bonded to the 
opposite end. During the PCR reaction the Taq polymerase enzyme cleaves the probe thus, releasing the fluore cent molecule from the quencher. The 
amount of fluorescent signal in the reaction increases and is measured. The expression levels of the genes of interest are normali zed again t the refer-
ence genes using the Oncotype Ox algorithm. 
UWOMJ I 81 :2 I Fall 2012 37 
HEALTH AND TECHNOLOGY 
geneti cs too l in perso na li zed cancer treatment is sure to become a real-
ity over the course of our med ical career . 
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Gastroenterology profiles: Dr. John Howard 
Lauren Sham (Meds 2014), Abdul Naeem (Meds 2014) , Joyce Zhang (Meds 2015) 
Faculty Reviewer: Dr. John Howard , MD, FRCPC (Departments of Medicine and Pediatrics) 
D uring the .. Transcending Border ., conference hosted by the Uni versity of Western Ontari o earli er thi year. Dr. John How-ard offered orne age advice to eager students: to focus on the 
things we can change. and ce lebrate our small successes. This genuine 
counsel is perhaps the result of a multitude of experi ences aimed at pro-
ducing pos iti ve change. Currently the Chief of Paediatri c Gastroenterol-
ogy and As istant Program Director fo r Paediatri c at Victoria Ho pita! 
in London. Ontari o, Dr. Howard has also held the position of Ass istant 
Dean of Undergraduate Medicine, where he spearheaded the develop-
ment of a new undergraduate curriculum. He is al o the Chair of the 
Canadian As oc iation of Phys ician for the Environment (CAPE). His 
pa sion for medical teaching i immediately felt the second he enter a 
lecture hall, and he has been recognized many times as the rec ipient of 
numerous teaching awards. 
As a kid. Dr. Howard had his heart set on becoming a veterinarian, 
but as he says. he j ust happened to •· tumble into medicine:· Looking 
back. he sees that th is is probably why he is in paediatrics: ·· ay ing ·My 
cow·s not performing we ll" is kind of like say ing ·My kid 's not perform-
ing we ll" - they' re both very observational !' ' He completed his medical 
training at Queen's Uni versity and his res idency in Internal Medicine at 
the University of Western Ontario with subspecialty training in Ga tro-
enterology. When practi cing adul t gastroenterology at Victoria Hospital 
in London, he shared the paed iatri c patients because they didn ' t have 
anyone to look after them pec ifi cally. In 2004. he made the switch from 
adults to mainly kids. He has the pri vilege of having a unique practi ce 
- he calls him elf a ··fami ly gastroenterologist" : hi major practice con-
i t of kids. but he doesn' t have to say goodbye to them when they ' re 
18. 
What does he I ike mo t about his j ob? Without hesitation, Dr. How-
ard says it 's about the life stori es, which is parti cularly true in pediat-
ri cs. ·'You get to look after them as kids. and then they grow up and get 
marri ed. and now they have kids!'' He thoroughly enjoys being part of 
people's li ves. This is especially due to his interest in the " doctor-patient 
relationship."' Challenging patient are often the ones that sti ck out in his 
mind. He mentions thi s one tough guy, with bad ga trointestinal disease. 
a guy that hould have been dead I 0 to 15 years ago from com pi ica-
ti ons but still carri es on . One night at 5 a. m., Dr. Howard gets a ca ll 
from him. finds out that he had lost his son very suddenly. and helps 
takes him through it over the phone. A nother patient of his with terribl e 
inflammatory bowel disease has major psychiatri c di fficulties. He sees 
the patient every four to fi ve years, but their entire medica l relationship 
is on e-mail because the patient has di fficu lty dea ling with face-to-face 
communi cation . ·'But it 's so interesting," he remarks, "The patient w ill 
show up at my kid 's performances and just say hi. So I know what the 
patient looks li ke. It 's a wonderful therapeutic relationship - and I don' t 
bill anything for it. " 
Dr. Howard takes hi phil osophy of the doctor-pat ient relat ionship 
directly into the running of his clinic. " [ have three kind of relationship 
w ith patients: pos iti ve energy, neutral energy. and negati ve energy. M y 
clinic are et up in thi s way. Most of my encounters are neutra l : I 'm in 
a high energy state. they ' re low. I tran fer some energy and the patient 
fee l better and take up my energy. Pos itive energy is when I'm high. 
they' re low. I see them through the interaction and give them energy -
but a the relationship develop , they give me energy w ith their trust and 
fri endship. and we ·re both energized. The bad kind is when I'm high. 
they' re low. and I give more energy and it j ust evaporates - the energy 
isn' t tran ferred:· He says that the key in medicine is to change states: 
negative to neutral. and neutral to posi ti ve. Just like relat ionship in li fe : 
some people suck energy from you. most fri end are neutral energy. and 
some are what you would call love, the traditional pos iti ve energy rela-
tionship. The positi ve energy doctor-patient relationship is ak in to love 
-a pro fess ional love. 
Hi ecret key to teaching? ee ing the log ic in a wrong answer. " I f 
you' re asking a student what he thinks thi s patient has. and the patient 
ha irritable bowel yndrome but the student says Crohn ·s di sease- you 
could just say ··No." Or you could say. '· J could ee how you might think 
that. but thi s is my perspect ive." He like to acknowledge and see the 
logic in a ' rong answer - otherw ise student j ust '' on ' t an wer. He sees 
it as a wonderf ul academic exercise to see j ust how that wrong answer 
came out. He also likes to be a personal professor. rather than a big 
professor. One of the ways he does thi is bringing in hi own patients 
to lecture - an exercise many students con ider to be their favourite part 
of cia s. He al o learned. though. there i a ri ght and a wrong time to 
do it. He used to bring in a patient that had been prev iou ly abused by 
a physician - ri ght in the fi rst part of medical school. " It was great for 
FIFE-ing. but people would get so wrapped up in the case and not look 
at the method! '. He has now learned to bring in more complicated cases 
in second or fourth year - at a leve l student can come to apprec iate. 
Dr. Howard's intere t in ecosystem health tarted wi th hi role in 
developing the new medical curriculum : he identi fied a huge vo id in the 
old curriculum that lacked the topics of health stewardship. advocacy 
and public health . A fter di covering a ne\ ecosystem health program in 
Guelph. he reali zed that public health can be taught to medical students 
through ecosystem health . ome of the issues he is work ing on through 
CA PE include: banning the cosmetic use o f pesti cides. hi ft ing to re-
newable energy. namely w ind power. and elimination of coa l generation. 
Dr. Howard believes that the environment ha a fundamental impact on 
our hea lth in a way that most of us are not aware of. K eeping in mind 
how our presence alters the environment may be the key in understand-
ing the increas ing prevalence of certain di eases. Though it can be chal-
lenging to balance his clini cal duties and his obligat ions to CAPE. Dr. 
Howard tries to achieve the balanced integrati on of the l \\ 0 by gi ing 
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grand rounds on eco ystem hea lth. encouraging students to become in-
terested in the fi eld. and being con cious of the impact of hi s cl inical 
practice on the environment. He poses the questi on to his students: are 
we doing the right things in medicine. not only for our patients but also 
for the environment? ·'Most people come into medicine with a [sense 
of the environment]. but they lo e it. My job is to maintain it and hope-
ful ly stimulate it. ' ' For patients. it comes in their own empowerment. 
" People will ask for their kids, · o Bob ha rohn·s di sease. how do I 
prevent the other two from getting it')' You could say, "Nothing," which 
is very di empowering. But you could tell them instead that there's thi s 
epidemic of Crohn · disease- it ' gone up at least I log unit ince my 
starting practi ce. nd I don' t know what that is - but I have to look at 
that and li ve as naturally as poss ible ... 
What does he ee for his future? ·'f'm retiring A pril I. 20 15! .. he says. 
w ith a chuckle. He ees himse l f as bei ng in a nice part of his career: not 
coasting. but ha ing opportuniti es he can pick for him el f. .. I can say no 
to thing becau e I'm retir ing in 3 ) ear ! .. He ays he '' ill probably go 
around the worl d and not be so \~ ark-ori e nted . but then likely will come 
back and work in the community in non-invasive gastroentero logy. "A t 
thi s point in m) li fe. I don' t worry about anyone. A Gl bleed doesn' t 
bother me. a I year old bleeding doesn ·t bother me. They used to. but 
I' ve seen so many and I won ·t be doing those types of cases ... He also 
would like to write a book on environmental is ues. but doesn' t want to 
pre sure him elf. " People ay the bad thing about the environment is -
where do you start? But they have grey coloured glasses on. I have rose 
co loured glasse on - and say instead. look at all the opportun it ies and 
di fferent place we can start." 
His advice to medical students: '·Remember who you were when you 
came into medica l school and the value that you had - hold onto them. 
Think about creating your own personal miss ion statement and keep to 
it ... His mis ion statement? "To be a patient centred phys ician who is 
accountable to our community and to deli ver that to students." M any 
students truggle w ith picking a specialty and exactly what they should 
do in li fe. Dr. Howard 's philosophy counter that idea: " Don' t get hung 
up on what you' re going to be. but more who you' re going to be.'' 
•'• Alberta Health 
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Dr. Yolanda Alcaraz-Limcangco 403-783-7810 
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Thinking like an emergency doctor 
Elaine Tang (Meds 2015), Roman Shapiro (Meds 2014), Kimberly Fielding (Meds 2014) 
Faculty Reviewer: Dr. Naveen Poonai MSc MD FAAP FRCPC (Department of Paediatrics/Internal Medicine) 
THE PRESENTING PROBLEM 
A previou ly healthy 14-year-old girl develops acute lower abdom inal 
pain and vomiting. The pain comes in waves, and the girl is in obvious 
distress. Her parents have now brought her to the emergency room. 
THE PATI ENT'S STORY 
The girl had been running and playing soccer with friend s outside when 
she suddenly had fe lt a sharp, radiat ing pain in her abdominal region. 
At first. she ignored it and continued play ing. but eventually the pain 
became so intense that she couldn 't stand. Becoming concerned, her 
parents tried to get her to stand, but she was unab le to walk. They car-
ri ed her to the car and drove her straight to the emergency department. 
Since the onset of the pain, she began vomiting intermittently. She is 
now curled on a stretcher and guarding her stomach. 
THE EMERGENCY ROOM 
The parents are frantic. Repeatedly, they have demanded that their 
daughter be given some form of ana lges ia or narcotics to control the 
pain . The girl's pain seems to be getting worse. The emergency doctor 
works quickly to first assess ABCDE: Airway, Breathing. Ci rculation, 
Disability, and Exposure. Outside of the girl's pain, it appears that the 
girl is stable. 
GENERAL APPROACH 
The most important thing to determine in children with abdominal pain 
is whether this is a life-threaten ing condition that will req uire immediate 
intervention. If not life-threatening, more time can then be taken to iden-
tify the proper cause of the pai n.1 There are three areas of exam inati on 
that are important: 
Histo ry - Use the hi story to try and understand the cau e of the abdomi-
nal pain . Ask about any trauma to the area. previou surgeri es, fever, 
vomiting, the locati on of the pain and pattern of symptoms.21 
Trauma: Abdominal trauma can be life-threatening, especially if 
organs are damaged. Remember that for some abdominal injuries, 
symptoms may not appear immed iately, such as left shoulder pain 
from a slowly deve loping splenic hematoma, or a duodenal hema-
toma from a lap seatbelt injury.32 
Characteristic of Pain: Obtain information about the onset, frequen-
cy, duration , characteri zation, and location of the pain. Spec ifi c diag-
noses have particular characteristic patterns of presentation.41 
• Associated Symptoms: Signs of fever and abdominal pain are often 
correlated with infectious etiologies such as gastroenteriti s, viral 
syndromes, or pharyngitis. Vomiting in connection with abdominal 
pain, especially without diarrhea can be indicati ve of life-threaten-
ing bowel obstruction or appendicitis. Vo lvu lus and intussusception 
should also be included on the differential and ruled out, although the 
latter is less likely in thi age group. A hi story of a cough hould also 
be eli ci ted because children with pneumonia frequently complain of 
abdominal pain . Lower urinary symptoms should be eli cited since 
abdom inal pain may be a presenting symptom of urinary tract infec-
tion (UT1).52 An often missed eti ology is a gynecologic emergency 
such as ovari an torsion .. ectopic pregnancy, etc .. necess itating a com-
plete gynecological hi story.63 
Past Medical History: Previous abdominal surgeries. UTis and pre-
existing conditions such as Sickle Ce ll Disea e shou ld be taken into 
cons iderati onn 
Physica l exa mination - Vital signs and detailed abdominal examina-
tion are essential.81 
• Appearance: Look at the patient 
Hypovolemia can be indicative of abdomi nal injury. vo lvulus, or 
intussuscepti ons 
Jaundice can indicate hepat iti s or hemolysis 
Vital Signs: Key features to keep in mind are fever. which would 
suggest an infection, tachypnea. which may indicate resp iratory ill -
ness or metabolic ac idosis, and hypotension, which can develop from 
intravascular vo lume loss or peritoniti s. 
• Abdominal E.:wmination: Look for di stention, li sten for bowel 
sounds. locali ze quadrant pain, and percuss for tenderness, rebound, 
or involuntary guarding. Rectal exam may be indicated. and stools 
should be observed for softness and blood. 
General Examination: Extra-abdominal findings can help determine 
the cause of abdomina I pain, uch as resp iratory symptoms sugges-
ti ve of pneumonia. altered heart sounds indicating either pericarditi s 
or myocard iti s, fl ank tenderness suggesti ve of pyelonephriti s or uro-
lithia i , or rashes/brui ses indicative of Henoch-Schonlein purpura. 92 
For sexually acti ve females with lower abdominal pain , bimanual 
pelvic examinations should be done to look for pelvic inflammatory 
disease, ad nexal masses or cysts, uterine pathologies, etc.103 The co -
tovertebral angle should also be percussed. 
Ancilla ry studies - Laboratory and radiographic testing should only be 
done if there are foca l concern that suggest a particular diagnosis that 
can be confirmed with imag ing/lab testing. 
Laborat01y Test: WBC, hematocrit. serum chemistries, urine dip-
sti ck. urine pregnancy te t, rapid Streptococcal antigen testing, etc . 
Imaging: Plain radiography, ultrasound. CT scan 
FAST: Focused abdominal sonography for trauma - performed in 
the emergency room to quickly determine free fluid in the abdo-
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men. III 
ECG: Can asse vo ltage, T changes and T wave abnormalities that 
can uggest peri cardia! disease 
ANA LGESIC US£ 
Chi ldren with acute abdominal pain should rece ive an effecti ve analge-
sic based on their level ofdi comfort .121 Whi le there have been concerns 
about the use of analge ics altering the accuracy of clinical findings. 
clinical tri als have shO\\ n that morphine analgesic use in chi ldren with 
acute abdominal pain i able to prov ide pain relief without significantly 
changing clinical examinations or determination of surgica l conditions. 
NSA IDs are al o acceptable for pain control. Despite the pre ence of 
thi s data current ob ervati onal studies indicate that children often do not 
rece ive adequate pain control in these acute circumstancesD 1 
T HE SPECIALIST EXAM 
In a debriefing by the parents. the emergency doctor conducted a quick 
te t to rule out potential I i fe-threatening cause of the girl ·s pain . When 
making a econdary urve) . think A MPLE: allergies. medicati ons. past 
illnesses. last meal. and events preceding the injury. 
Histo ry -The parent did not report any signifi cant trauma incurred 
during the soccer game. Other than the lower abdominal pain, the girl i 
not complaining of discomfort anywhere else. She i localizing the pain 
to her right lower abdominal quadrant and radiating to her back. She 
describes the pain to be sharp and tabbing. She also report other re-
cent --stomach pains" that resolved pontaneously, believing these pains 
may have been due to menstrual cramping. he ha no prev ious medical 
conditions. he is currently experi encing some nausea, and has vomited 
tw ice in the Ia t few hours. 1 ~~ 
Ph ysica l exa min at ion - The patient does not appear to be hypovole-
mic or jaundiced. She has a unilateral. tender adnexal rna s with some 
tenderne to palpati on. There are no other remarkable findin gs. Stoo l 
sample have been norm a l. 1 1~ 
A nci lla ry stud ies - Blood i drawn and a CB shows normal level o f 
WBC and hematocrit. ~ - H leve l are ordered. and the results are not 
suggesti ve of an ectopic pregnancy. Since she has lower abdomina I pain, 
it was decided that a pelvic ultra ound would be carried out. Results 
showed an enlarged ovary to one ide. w ith multiple small immature 
follicles along the periphery.164 Conce rned about cyst . cancer. or other 
pathologie . a co lor Doppler I and CT scan were per fo rm ed to show 
morphologica l and phy iolog ical change in the ovary, and to assess 
blood fl o'' · Very litt le intraovari an venous fl ow was present. 1H 
SOLVING THE MYSTERY 
A fter taking a detailed history and imaging. the diagno i of ovari an tor-
sion wa made with the help of a gynecologic con ult. "~ The pre ence 
of an enlarged ovary with a decrease in intraovari an venous flow alerted 
phys ician thi diagnosi . Laparo copic urgery was quickly booked. In 
the meantim e. morphine was used to control the girl · pain unti l she was 
able to go to the OR. 
CONCLUDING REMA RKS 
Ovari an torsion can ea ily mimic other Gl causes of acute abdominal 
pain uch as constipati on, bowel obstruction, appendicitis. intussuscep-
ti ons. gastroenteriti • renal co lic, ans mesenteri c adeniti . 1 9~ Despite it 
rari ty in presentati on. ovari an tor ion hould still be on the di f ferential 
diagnosis when females pre ent w ith severe. acute, lower abdominal 
pain . Due to its variable pre entati on and often non-specific findings. 
the diagno is of ovari an torsion i often missed and ramifi cati ons for the 
delay can result in a necroti c ovary. Laparoscopy is u ed for confirma-
tion of diagnosis and treatment, usually on an in-patient basis. Prompt 
diagnosis and timely management help save the adnexal structures from 
infarction and facilitate a peedy recovery. 20~ 
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A case of adult intussusception: a curious 
presentation 
Yikang Lin (Meds 2014), Stephen Cornish (Meds 2015) 
Faculty Reviewer: Dr. Patrick Colquhoun , MD (Department of General Surgery) 
I t is we ll established that a diagnos i can be made solely on the basis of a patient's hi tory in the maj ori ty of cases. Phys ical examination may reveal more clue to the patient 's complaint di agnosti c tests are 
used to identify, a es , and confirm any phys iological ba is for disea e. 
However. a thorough history and good clinical acumen contribute most 
to a medica l diagnos is and treatment se lection. Thi daunting idea is 
also reassuring. in that there is no substitute for a sound diagnostic ap-
proach that one can gain from experience. There is, however. always 
opportuni ty for a rare occurrence, a peculiar presentation. a proverbial 
' zebra· to slip past our detection despite our most diligent efforts. Dis-
guised by common or vague symptoms rather than stripes. these ·zebras· 
are a chance to step outside of the usual diagnostic proces , summon a 
protracted differential diagnos is from our training, and regard an un-
so lved medical problem w ith new eyes. When the pattern of everyday 
medicine are broken by such a case, the importance of an astute doctor 
is starkl y illuminated. 
The fo llowing case was described by Yalamarthi and mith.1 A 42 
year old male w ith a three day history of melena pre ented to his gen-
eral practiti oner. who referred the patient for con ultation. He had been 
prev iously inve tigated for iron defi ciency anemia, with no cause hav ing 
been identi fied. At the time of consult. the patient's haemoglobin was 
low (86 g/L) and was suggesti ve of an iron defic iency etiology. The ini-
ti al investigation that wa performed was an upper Gl endoscopy. which 
revealed minimal esophagitis. The absence of signifi cant esophagitis is 
of interest because iron defi ciency has been known to coincide with both 
hiatal hernias and esophagiti .2 The patient elected for a conservati ve 
in vesti gati ve approach and under>vent a normal barium enema. 
Since thi patient 's initial presenting complaint was an acute history 
of melena, it may be help ful to rev iew the di ffe rential diagnosti c thought 
process that would be triggered by thi s symptom. Melena refers to black. 
tarry stool caused by the presence of blood. The tarry appearance i cre-
ated by the digestion of red blood cells and their contents (spec ifically 
the oxidation of iron in hemoglobin) by the acti vity of the G I tract as it 
passes through the intestine and co lon.3 For the blood to be dige ted in 
thi s way, its source must originate early in the gastrointestina l tract; thi s 
fact allows physicians to classify a Gl bleed as being an ' upper G l bleed' 
by the presence of melena. About 90% of melena originates proximal 
to the ligament ofTreitz (a structural support connecting the duodenum 
to the diaphragm), but some cases can originate in the mall intestine 
or prox imal colon . ~ Con verse ly, the presence of bright red blood in the 
stool is indicati ve of a · tower Gl bleed·, from the distal colon or rectum. 
This distinction can be very helpful in pursuing a diagno i . 
Causes of upper G I bleed can vary greatly, and a detailed history 
is critical to ruling in or ruling out these potential ituation . Poten-
tial bleeding causes in the upper GI tract include peptic ulcer disease, 
esophageal varices, portal hypertensive gastropathy, malignancies, an-
giodysplasia. and aorto-enteric fi stula5 Peptic ul cer di ease is a com-
mon cau e of upper Gl bleeding. and is seen in patients with a history 
of Helicobacter py lori in fect ion. Marginal or anastomotic ulcers can be 
present in patient w ith gastroenteri c anastomosi . E ophageal vari ces 
and portal hypertensive gastropathy can be een in patients who have a 
history of alcohol abuse or li ver disease. Malignancie can occur in the 
upper Gl tract in patients with a history of smoking. alcohol abuse. or 
bacteri al infections such as He/icobacter py lori. In patient with renal 
disease. aorti c tenosis. or hered itary hemorrhagic telecta ia. re ultant 
angiodysplasia can lead to bl eeding in the upper G I tructures. Final-
ly, an aorto-enteri c fi stula can develop in patients who have a history 
of aorti c aneury m or an aortic graft . A n a sessment of medications 
is also necessary to determine i f there may be a pharmacologica l basis 
for the upper Gl bleed, which can be seen in the fo ll owing situations: 
non- teroidal anti-infl ammatory drugs leading to pepti c ulcer disease, 
irritation of the esophagus by medications leading to pil l esophagitis, 
anti-coagulants which promote bleeding. and bi muth or iron which can 
give stoo l the appearance of melena w ithout causing a bleed.5 
The patient wa een again in clini c. and upon thi s second visit he 
complained of left upper quadrant pain.1 He wa till anemic at thi s 
time. with a haemoglobin of 98 giL. despite being advised to take iron 
supplement after hi fir t consultation. There were no igns of overt 
blood los . and no apparent clues to suggest a hidden ource. A barium 
meal follow through showed distorti on of the terminal ileum. which was 
initially assessed as ex trinsic compress ion of the intestine by the sig-
moid co lon. Further investigation using computed tomography (CT) 
showed an abnormally thickened region of the ileum. On the scan. thi 
region had a target-l ike appearance as we ll a intra-l uminal fat present, a 
fi nding consistent w ith our gastrointestinal ' zebra' condition. 
Our patient 's fir I in vestigation v\ ere barium tudies. The contents 
of the Gl tract are di fficult to di scern on an X-Ray. so barium salts. 
which are non-tox ic rad io-opaque, are in erted to help w ith visualiza-
ti on. The fir t test performed was a barium enema. which in ve ti gates 
the co lon. After a patient empti es their co lon. a well- lubricated enema 
tube i inserted into the patient 's rectum . The colon can be fill ed with 
barium alone - a ·'single contrast" barium enema - or barium followed 
by air - a " double-contrast' ' barium enema6 X-Ray fluoroscopy reveals 
details about the inte tinal lumen and mucosa, with double-contrast 
barium enemas prov iding better information on the lining. Our patient 's 
les ion was located above the range visible via a barium enema. The sec-
ond investi gation. a barium meal, is a similar proce that investigates 
foregut structure instead of the colon.7 This in estigation revealed a 
compress ion of the terminal ileum. With CT imaging. hallmark signs of 
an intus u ception were vi uali zed, specifica lly a target-shaped appear-
ance indicating overl apping bowel wall . and intra-luminal fat. which 
indicates entrapped me enteri c fat. 1 
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A n intussusception is the telescoping of one segment of bowe l into 
an immediately adjacent segment of bO\\ eP It i found far more com-
monly in pediatri c populations (95% of all intussusception cases are in 
children), and accounts for less than 5% of adult ca es of gastrointestinal 
obstruction. In children. it i almost always benign and idiopathic. and 
resolves with the barium enema that is used to diagno e it - the hydro-
tati c pressure of barium fluid- with or without air- will cause the tele-
coped bowel to reduce into anatomical position9 Furthermore, children 
often pre ent w ith the classic triad of intus usception ymptom : vomit-
ing. rectal bleeding. and abdominal pain. In adults, intu susception often 
presents with vague abdominal symptoms, which a careful clinician may 
be able to di cern . Abdominal pain assoc iated with intussusception is 
genera lly peri od ic and intermittent. and is sometime accompanied by 
blood in vomit and/or stoolw Furthermore. intu su ceptions in adults 
are rarely idiopathic. with malignant growths accounting for 6-30% of 
adult intussusception case . and maj ority occurring from benign pathol-
ogy. Our patient had a traumati c ul cer in a M eckel ' di verticulum that 
erved as the lead point for the telescoping to occur. 
Meckel's di verti culum is a congenital anomaly of the small bowel. 
occurring in 2% of the population, and more common!) seen in males 
than females.11 I f it is present in an indi vidual. it is u ually found within 
two fee t of the ileocecal va lve. This vestigial structure represents an in-
complete closure of the omphalome enteric or vitelline duct, which con-
nects the midgut of the developing embryo to the yo lk ac while in utero. 
A Meckel's diverti culum is typica lly asymptomatic, with only 2% of 
cases actually deve loping any complicati ons over their li fe time. As wa 
seen in our patient. bleeding from the di verti culum i painless, and can 
result from mucosa l ul cerati on within ectopic gastric ti ssue. This ecto-
pic ti ssue can continue to produce secreti ons that are characteri sti c of 
the tissue·s embryo logica l origin. such as acid and protease-containing 
dige ti ve fluid . These secretion can gradually break down the muco al 
lining of the di verti culum causing ulceration and bleeding. 
The fi nding of melena in thi ca e wa curious because the Meckel 's 
di verticulum was located in the di stal ileum. A s was prev iously men-
ti oned. gastro-inte tina! bleeding from the lower digesti ve tract (distal 
to the ligament of Treitz in the duodenum ) would normally pre ent a 
bright red blood in the stool. The approach presented by Cappell and 
Friedel for the eva luation of acute upper gastrointe tina I bleeding state 
that some ca es of melena can arise from pathology in the distal small 
bowel and even the prox imal co lon." With thi s in mind. thi s case trul y 
was atypica l: an uncommon pre entation of an unu ual pathology. 
There are generally two options in treatment - rc ection of the in-
volved bowel secti on , or reduction - i.e. returning the bowel to ana-
tomica l po ition. Generally, pediatri c ca e ofintus u ception will be re-
olved via reduction of the telescoping regions, with the option to re cct 
the affected region if it is irreparably damaged.12 In adult patients, due 
to the high preva lence of malignant tumor and the assoc iated ri sk of 
di emination if reduction is attempted, the preference i for re ection. 
Colo-anal intussusceptions are the notable exception. as reducing could 
pare the anal phincter, which is needed to retain bowe l continence, a 
we ll as po !-traumatic and idiopathic intussusceptions in which the ri sk 
of malignancy is insignificant. 
Our patient unden ent a laparoscopic procedure under general ane -
theti c to re ect a ection of his small bowel. 1 Depending on the amount 
of hea lthy bowel left after resecti on. the remaining bowel can be recon-
nected, or an ileo tomy can be performed in which remaining bowel 
is directed through an opening in the abdomen to a drainage bag. Our 
patient had approx imately I foot of bowel removed, thus his remaining 
bowel segment were reattached. He made an uneventful post-operati ve 
tay and made a full recovery to normal bowel function. 
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Helicobacter pylori: hiding in the modern miasma 
Justine Denomme (Meds 2015) and Jason L. Chan (MD/PhD 2017) 
Faculty Reviewer: Dr. Carole Creuzenet, PhD (Department of Microbiology and Immunology) 
W hen lgnaz Semmel we is proposed and demon trated that hand-washing wou ld decrease the incidence of puerperal fever in the mid-nineteenth century. he was ignored, criti cized. and 
rid icu led. Miasma. or bad air. was be lieved since ancient tim es to cause 
disease. and consequently, hand-washing had no place in medical care. 
Of course. thi is no longer the case, but decades pa sed before Semmel-
weis· recommendations gained widespread acceptance. His di scovery 
was controversia l and met with resistance. Eventually. the germ theory 
of disease replaced the miasma theory. and Koch·s postu lates prov ided 
a concrete method to establish a causa l relationship between a microor-
ganism and a disease. De pite the struggles of earli er researchers and 
clinician to advance medicine. resistance to new knowledge and dis-
coveri es sti ll prevails. The story of the bacterium Helicobacter pylori 
provide a modem example of thi s res istance. 
Today. when a person is diagnosed with peptic ulcer disea e (PUD) 
and an H. pylori 
infection. they are promptl y treated w ith a brief course of two anti-
biotics.1 Elimination of the bacteri al in fec tion is associated with more 
rapid healing of ulcers and reduces the ri sk of relapse.1 The associa-
tion between bacterial in fection and pepti c ulcers was di scus ed w ithin 
scientific literature as early as the late 19'h century but a definitive l ink 
between peptic ulcer disease and spec ific bacteri a was not e tablished 
until 1984 2 Furthermore. in 1995. a tudy of treatment patterns of peptic 
ulcer di ea e in the United States showed that only 5% of patients were 
being treated wi th antibiotics in order to eradicate H. pylori3 Why did 
this happen? Firstly. the characteri tics of H. pylori made it difficult to 
study. Secondly, there was already a we ll-established theory regarding 
the etiology of peptic ulcers when the bacteri a were first success fu lly 
cu ltured. Finally, the medical communi ty was more hesitant than the 
sc ientific community to accept infection as causative of peptic ulcers. 
Unlike many other disease-causing bacteri a, H. pylori did not easily 
fu l fill Koch 's postulates for peptic ulcer disea e. The econd postul ate 
states that a disease-causing microorganism must be isolated and grown 
in pure culture . ~ With the advent of microscopy and germ theory. early 
bacteriologists and patho logists ident i fied bacterial colonies associated 
with ulcer tissue samples on several occasions.' However, H. pylori was 
not successful ly cultured unti l 1982, by Drs. Barry Marshal l and Robin 
Warren.2 The bacteri a are espec ially difficu lt to cu lture even today be-
cause they grow I 0 to 15 times more slow ly than Escherichia coli. are 
microaerophi l ic, and require specific cu lture media. Interestingly, Mar-
shall and Warren's early experiments were on ly successful when a plate 
that was accidentally left over the Easter weekend instead of being dis-
carded after 48 hours without growth grew colonies.2 
Furthermore, Koch's thi rd postulate states that disease shou ld be re-
produced when the cu ltured microorgan ism is introduced into a healthy, 
susceptible h ost. ~ This postul ate was memorably proven by Dr. Barry 
Marshall when he ingested a culture of H. pylori i olated from a patient 
wi th gastriti s.1' Thi s was the only way to fu l fill Koch' third postul ate 
at the time because most H. pylori strains only infect humans.6 This 
proved to be problematic for earl y animal studies on ga triti s. Bacteria 
assoc iated with infl amed gastri c mucosa of rhesus monkeys and with 
human gastri c ti ssue was studied by J. L. Doenges in 1938 and later by 
Freedberg and Barron in 1941 .5 Unfortunate ly, the bacteria from rhesus 
monkeys were hi stologically different from th ose in humans and bacte-
ri a were more difficult to identi fy in human ti ssue samples. Therefore, 
it could not be definitively concluded that bacteria caused gastric in-
fl ammation-' Later. when Dr. Marshall initi ally attempted to implement 
Koch's third postulate. he unsuccess fully attempted to transfer H. py lori 
cultures to piglets7 It was only more recently that more suitable animal 
models were developed.'·9 Fulfilling Koch's postulates in the case of H. 
pylori was more difficult than for many other types of bacteria. These 
characteri sti cs of H. pylori delayed the development of efficient meth-
ods for its study can partially explain why it was not easily estab lished 
as one of the causes of peptic ulcer di sease. 
A lthough identi fy ing H. py lori was difficult. once Mar hall and War-
ren presented their findings to the world. other microb iologists verified 
and accepted them. However. gastroenterologi ts were more reluctant 
to accept thi s new information . Eventually. Drs. Marshall and Warren's 
work became formally recogni zed when they were awarded the obel 
Pri ze in Physiology or Med icine in 2005 . In his obel Lecture. Dr. Mar-
shal l stated that the greatest obstacle to his work was that the cause of 
peptic ulcer disease was .. already known .. _10 When Warren and Marshall 
isolated and cultured H. pylori. H2 receptor antagonists were an estab-
1 ished treatment for peptic ulcer disease. 11 The use of these drugs. which 
decreased ac id secretion in the stomach. helped validate a theory of the 
etio logy of peptic ulce r disease at the time: the stomach was secreting 
too much ac id or the muco al l ining was les resistant to stomach ac id, 
causing damage. ulcers, and pain. It was thought that intrinsic factors 
such as psychological stress or habits such as moking made the tom-
ach l ining more vulnerabl e to damage. 11 In the case of ulcer caused by 
H. pylori. i sugge ted that it is main ly the bacteri al infection which 
results in increased ac id secretion due to the body 's reaction to the infec-
tion .12 Another predominant theory was that the stomach was too ac idic 
for bacteri a to grow. 11 Therefore, when bacteria were historical ly ob-
served on samples of gastri c ti ssue, they were thought to be artefacts. 5 
Based on what had been traditional ly taught in medica l schools at the 
time of the discovery of H. pylori. Drs. Marshal l and Warren's research 
wou ld have been very extraordinary. 
There are severa l other reasons why the medical community did not 
eagerly embrace Marshall and Warren's findings. To begin. testing for 
H. pylori was origina lly invasive and inaccurate and physicians did not 
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want to treat peop le with antibio ti cs unnecessarily for fear of antibiotic 
resistance.13·1• Secondly, throughout the 1980s. the pharm aceutical in-
dust!)' continued to pursue the development of treatments that did not 
account for a bacter ial etiol ogy of PU0 .15 In 1988, proton pump inhib i-
tors. such as omeprazo le. were launched as an alternati ve to H2-antag-
onists.1 5 T he pharmaceutica l company producing omeprazo le organized 
an internati onal y mpos ium on PUD that year. featuring 33 notable ga -
troenterologi st . yet only one of the 67 po ter and abstracts pre ented 
dea lt with H. pylori. 15 Finall y. continuing med ical education may not 
have been a effecti ve at keeping physicians aware of changes in med i-
cal practi ces in the past as it i todayY• I t was trad itionall y based on se l f-
directed learning and el f-as essment. which could lead to deficiencies 
in medical knO\\ ledge and a lack of accountabi lity. 16 In add ition. some 
cont inuing medical education ha hi torically been funded by the phar-
maceutical indust!)'. w hich could potenti al!) introduce bias into the cur-
riculum .1 7 Accepting new theories that cha llenge previously -estab li shed 
belief can be very d i ffi ult. In thi ca e. the lack of resource and infor-
mation I ikely con tri buted to th e delay in eradication of H. pylori becom-
ing the standard of patient care for gastriti s and PUD. 
One of the most importan t factor in the acceptance of the eradica-
tion of H. pylori from the tomach s of symptomatic patients was the 
di covery that H. pylori i carci nogenic. 18 Re earch into the relationship 
of H. pylori and certai n cancer began short ly after its di covery and 
by 1994 the Internationa l Agency for Re earch on Cancer reviewed the 
ava ilable literature and concluded that people infected with H. pylori 
are at increa ed ri k for developing gastri c adenocarcinoma and ga tri c 
B-cell mucosa-associated ly mpho id ti s ue (MALT) ly mphoma. 18 Gas-
tri c adenocarc inoma is a lead ing cause of cancer death wor ldw ide and 
is typi cally associated wi th a poor prognosis. 19·2" lntere ting ly. MALT 
ly mphoma can be treated by eradication of H. pylori and it has been 
suggested that H. pylori eradicati on could help prevent future gastric 
cancer. 21 Cancer is one of the most notorious diseases in our oc iety. 
and the association of /-1. pylori infecti on wi th malignant disease was 
further evidence to upport that an H. pylori infection requires medical 
attention . 
T he journey toward e tabl ishing an eti o logy for peptic ulcer disease 
wa long and exceedi ng ly difficult. H. pylori posse es many charac-
teristics th at make it difficult to cu lture and e tabli sh a cause-and-effect 
rel ation ship with peptic ulcer di ease. Furthermore, the idea wa un-
appea ling to many becau e it cha llenged prev iously estab lished vie\·\ S 
and challenged phy icians to rev i iL tradi tional medica l knowl edge. In 
order to truly provide the best possible care to patients. phys ic ians must 
embrace the dy namic, urpri ing, and ever-chang ing aspects of the field 
of medicine. With improved continuing medical ed ucation and wi th im-
proved access to medical journal online. thi s has never been more pos-
sible. Many fie ld of medical cience. inc luding Helicobacter pylori, are 
still acti ve areas of research loca lly and g loba ll y and emerg ing knowl-
edge w ill certainly continue to challenge phy icians to improve med ica l 
practices in the future. 
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